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ABSTRACT 
 
The adult heart is capable of remodelling in response to different pathological stimuli; 
in most cases, a phase of compensated hypertrophy evolves into frank dysfunction and 
heart failure. To identify microRNAs able to prevent cardiac hypertrophy and preserve 
cardiac function, we performed a high-content microscopy, high-throughput functional 
screening for human microRNAs able to reduce neonatal cardiomyocyte (CM) cell size 
using a whole-genome microRNA library. The most effective anti-hypertrophic 
microRNA was hsa-miR-665. In a model of transverse abdominal aortic constriction 
(TAC) in 8 weeks old CD1 mice (n=14 per group), AAV9-mediated delivery of miR-665 
showed remarkable capacity to protect against pathological cardiac hypertrophy and 
preserve function over time. This effect was observed when the vectors were delivered 
either before (LVEF at 60 day after TAC: 51.3% ±5.8% in treated vs 34.82% ±0.77% in 
controls; P<0.005) or after hypertrophy onset (LVEF at 60 days after TAC: 57.5%±5.60% 
in treated vs 28.4%±15% in controls; P<0.001). Global mRNA changes in hearts treated 
with miR-665 were evaluated by mRNA deep sequencing. All the 43 genes, for which 
siRNA were available, out of the 67 genes that were found to be significantly expressed 
≤2 fold over control were individually down-regulated by specific siRNAs and tested for 
being direct miR-665 targets. This approach identified three sarcomeric proteins as 
direct mediators of miR-665 activity, namely Enah, Fhl1 and Xirp2, which are known to 
be involved in sarcomeric mechanotransduction and myofibrillar remodelling. In 
conclusion, miR-665 represents an important tool to decipher the molecular 
mechanisms of hypertrophy and offers a potential lead for the development of new 
biotherapeutics. 
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INTRODUCTION 
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1.1 The heart 
The heart and its study has fascinated artists, philosophers and scientists since antiquity. 
Historians mutually agree that the start of modern cardiovascular medicine took place 
with the work of William Harvey and the discovery of blood circulation. 
 
“The heart . . is the beginning of life; the sun of the microcosm . . for it is the heart by whose 
virtue and pulse the blood is moved, perfected, made apt to nourish, and is preserved from 
corruption and coagulation; it is the household divinity which, discharging its function, 
nourishes, cherishes, quickens the whole body, and is indeed the foundation of life, the 
source of all action.” William Harvey, 1628. 
 
Taber’s Medical Dictionary defines the heart as a hollow, muscular organ that pumps 
blood through the circulatory system [1]. Blood is fundamental in providing the body 
with nutrients and oxygen whilst collecting and transporting metabolic waste from the 
periphery to kidneys and lungs where it is respectively filtered and oxygenated.  
The heart is the first organ to form and function during embryogenesis in vertebrates 
[2]. In mammals and birds four chambers form the heart: upper left and right atria; and 
lower left and right ventricles [3].  The wall delimiting each chamber has a structure 
composed of three layers: an outer part called epicardium, the middle part called 
myocardium (the cardiac muscle) and the inner part called endocardium, which lines 
the chambers and covers the valves. The heart is then enclosed in the pericardium, a 
fibro-serous sac that surrounds the organ generating an anatomical structure called 
pericardial cavity, which contains serous fluid to prevent friction as the heart beats.  [4] 
(Figure 1).  
1.2 The cardiomyocyte 
The contractile portion of the heart is the myocardium. It is mainly composed of 
cardiomyocytes (CMs), which are the building blocks of cardiac striated muscle. In light 
phase contrast microscopy, the shape of isolated adult CMs is rectangular and 
characterised by a typical cross-striated pattern [5]. Adjacent CMs are joined together at 
their extremities, on the longitudinal axis, by a complex structure termed as the 
intercalated disc (ID).  IDs are composed mainly by three main structures: the 
desmosome, which functions as a cell anchor, the adherens junction (AJ), which 
provides cell strength, and the gap junction (GJ), which couples cells electrically and 
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metabolically. These structures closely connect the cytoskeleton of adjacent CMs and 
are fundamental for the proper cardiac function ensuring the fast propagation of the 
electrical signal that initiates contraction thus generating a coordinated mechanical 
syncytium [6]. The lateral membrane of CMs is characterized by different structures such 
as costamers and focal adhesions, which are responsible for linking sarcomeres to the 
extracellular matrix (ECM) [6] (Figure 1).  
1.3 The sarcomere 
The motor function of CMs is based on sarcomeres, which confer to the CM cytoplasm 
its characteristic cross-striated appearance. Sarcomeres can be defined as highly 
ordered arrays of myosin (thick) and actin (thin) filaments. The scaffold of these arrays is 
titin: a giant protein (1 mm length) mostly composed of immunoglobulin (Ig) and 
fibronectin-like (Fn) domains, which serves as a molecular ruler for sarcomere assembly; 
the phosphorylation state of specific domains of titin is responsible for the elasticity of 
cardiac muscle [7].  The N-terminus of titin is bound to the Z-disk, a complex protein 
structure that defines the sarcomere extremities [7]. Thin filaments, which are 
composed of actin, tropomyosin and troponin are also bound to the Z-disk. Another 
important protein that co-ocalizes within the Z-disk is α-actinin, which binds both titin 
and actin [5] . 
Thick filaments are bipolar and they are joined together by myomesin in 
correspondence to the M-line [5]. They span along titin from the M-line towards the 
extremities of the sarcomere so defining the A-band, which corresponds to the entire 
length of a thick filament [7]. The region that surrounds the M-line is termed the H-zone 
and is characterized by the prevalence of thick filaments that are not superimposed by 
thin filaments [7]. In comparison, the I-band is the region that surrounds Z-lines and is 
characterized by the prevalence of thin filaments, which are not overlapped by thick 
filaments [7]. Cardiac muscle contraction relies on the possibility of thin filaments to 
slide on thick filaments, thus shortening muscle fibers. The frequency of subsequent 
cycles of contraction and relaxation is paced by the level of cytoplasmic calcium (Ca2+), 
which interacts with the troponin/tropmoyosin complex inducing conformational 
changes that expose the myosin’s binding site on actin filaments allowing the globular 
head of myosin to bind thin filaments [8]. During contraction, the myosin globular 
domain moves thin filaments towards the centre of the sarcomere. This sliding induces 
a conformational change that moves Z-lines together, thus shortening H- and I-bands 
whereas the A-band  length remains unchanged [5] (Figure 1).     
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1.4 The problem 
Despite recent advances in cardiovascular surgery and therapy, cardiovascular diseases 
(CVDs) are responsible of over 17 million deaths each year, corresponding to 31% of all 
deaths worldwide (http://www.who.int/cardiovascular_diseases/en/). The burden of 
CVD is no longer restricted to the high-income population, since 80% of these deaths 
occur in middle- and low-income countries. Since the adult heart is a dynamic organ, 
capable of significant remodelling in response to different extrinsic and intrinsic stimuli, 
the majority of the pathological stimuli first induce a phase of cardiac hypertrophy, 
which consists of the growth of the heart primarily through an increase in CM area [9]. 
The individual CM growth in length and/or width leads to an increase in cardiac pump 
function and a decrease in ventricular wall tension, initially leading to a state of 
compensated hypertrophy [10]. However, in the long term, myocardial hypertrophy 
often evolves in a form of decompensated hypertrophy, which predisposes individuals 
to heart failure, arrhythmia and sudden death [11, 12]. Therefore, cardiac hypertrophy  
and heart failure represent interesting targets for the development of novel 
biotherapeutics able to interfere with this processes. 
1.5 Cardiac hypertrophy 
During the foetal phases of heart development, CMs rapidly proliferate. However, 
immediately after birth proliferation stops, often after a final cycle of acytokinetic 
mytosis (karyokinesis without cytokinesis), which leaves a fraction of adult CMs 
binucleated [13]. Thus, the predominant form of heart postnatal growth is due to CM 
hypertrophy, a process that is mainly activated by the functional pressure overload that 
the heart walls are forced to face immediately after birth and is further stimulated by 
high levels of pro-hypertrophic circulating hormones, such as insulin-like growth factor-
1  (IGF-1) and growth hormone (GH) [14].  The same happens to the mother’s heart 
during pregnancy, and to the hearts of athletes as a result of extreme and/or repetitive 
exercise [15] [16]. In all the abovementioned cases, hypertrophy can be defined as 
physiological. Physiological hypertrophy is an adaptive process aimed at the decrease 
of the ventricular wall stress by increasing the thickness of ventricular wall. The 
phenotype of physiological hypertrophy is mild (≤10-20% of increase in total heart 
mass), coupled with a preserved or increased cardiac function, induces a net increase in 
ventricular angiogenesis and is reversible. At a morphological level, exercise-induced 
hypertrophy is typically not accompanied by an accumulation of collagen in the 
myocardium [17].   
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In contrast, pathological hypertrophy is generally induced by a prolonged wall stress 
caused by disorders such as systemic or pulmonary hypertension, myocardial infarction, 
coronary artery disease, genetic mutations, diabetic and metabolic cardiomyopathy, 
viral and bacterial myocarditis, valvular insufficiency and congenital heart defects. 
Pathological hypertrophy characteristically evokes a specific molecular signature, which 
is characterized by the re-activation of the so-called foetal cardiac gene program [17]. 
This program includes the induction of mRNAs for atrial natriuretic peptide (ANP), β -
myosin-heavy-chain (βMHC), α -skeletal actin (sk-α actin) and brain natriuretic peptide 
(BNP). Moreover, genes encoding for calcium-handling proteins (Serca2a and Ryr) are 
usually down-regulated [17].  
On the contrary, in models of physiological hypertrophy (exercised rats), this condition 
is characterized by increased expression of α -myosin-heavy-chain (αMHC) [18] and 
SERCA2a [19] and no reactivation of the foetal gene program.  Furthermore, 
pathological hypertrophy triggers a metabolic transition in the heart from an oxidative 
toward a more glycolytic metabolism [20]. This metabolic switch in substrate utilization 
may be a protective response, improving the ratio between ATP production and oxygen 
consumption [20]. This scenario is reminiscent of what occurs during foetal cardiac 
development both in terms of metabolism and gene expression. At the morphological 
level, pathological heart hypertrophy, is typically associated with loss of myocytes and 
fibrotic replacement, cardiac dysfunction, and increased risk of heart failure and sudden 
death [11]. 
1.5.1 Concentric and eccentric cardiac hypertrophy  
The mechanism by which cardiac hypertrophy can be considered adaptive follows the 
Laplace’s law, which defines wall tension as an inverse function of wall thickness 
(tension = (pressure x radius)/(2 x wall thickness)). Cardiac hypertrophy can be classified 
as either eccentric or concentric, based on the geometry of the heart and the 
sarcomere’s organization of individual CMs. Concentric hypertrophy refers to an 
increase in relative wall thickness and cardiac mass, with a small reduction or no change 
in chamber volume and is characterized by a parallel pattern of sarcomeres addition 
leading to an increase in myocyte cell width [11] (Figure 2).  Conversely, eccentric 
hypertrophy consists in an increase in cardiac mass, depending on the addition of 
sarcomeres in series, with increased chamber volume and a wall thickness that may be 
normal, decreased, or increased [11]. 
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Both phenotypes can develop as a consequence of physiological and pathological 
stimuli. For instance, a pathological stimulus causing pressure overload produces an 
increase in systolic wall stress, which results in concentric hypertrophy [11]. Conversely, 
a stimulus causing volume overload produces an increase in diastolic wall stress and 
results in eccentric hypertrophy [11](Figure 2). During pregnancy and in athletes used 
to prolonged aerobic exercise (also referred to as endurance training, isotonic or 
dynamic exercise e.g. long-distance running, swimming), the heart underwent to 
eccentric hypertrophy characterized by chamber enlargement and a proportional 
change in wall thickness, whilst eccentric hypertrophy in pathological conditions 
(myocardial infarction or dilated cardiomyopathy) is generally associated with thinning 
of the ventricular walls with preferential lengthening of CMs. Strength training (also 
referred to as isometric or static exercise, e.g. weight lifting, wrestling, throwing heavy 
objects) results in a pressure load on the heart rather than volume load and concentric 
hypertrophy [21] [11]. The heart can transition from a normal state to a state of 
physiological hypertrophy and back, although pathological hypertrophy that produces 
heart failure may be less reversible (Figure 2). 
1.5.2 Molecular mechanisms of cardiac hypertrophy 
Cardiac hypertrophy is primarily triggered at the CM level by a defined number of 
hypertrophic stimuli. Depending on the kind of stimulus, the transduced signals will 
converge on a specific subset of intracellular pathways that finally determine specific 
changes in gene expression. These changes in gene expression define the molecular 
signature of both physiological and pathological hypertrophy (The main pathways 
involved in either pathological an physiological hypertrophy are summarized in Figure 
3).  
1.5.2.1 Signalling pathways involved in pathological hypertrophy 
1.5.2.1.1 G protein-coupled receptors 
G protein-coupled receptors (GPCRs) play a pivotal role in the regulation of cardiac 
function and adaptation to changes in hemodynamic load. The most important 
myocardial GPCRs include adrenergic (α- and β -adrenergic) and muscarinic receptors. 
These receptors are respectively coupled with three main classes of hetero-trimeric 
GTP-binding proteins, Gs, Gαq/Gα11 and Gi, which are responsible for the transduction 
of agonist- or antagonist-induced signals [17].  It is important to underline that β-
adrenergic receptors are homogenously expressed in all cardiac cell type (i.e. cardiac 
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smooth muscle cells and cardiac fibroblast) and in a cell-type dependent manner they 
exert distinct effects.  
 
Gq/G11 signalling 
Pathological stimuli such as pressure overload, hormones and vasoactive factors 
(angiotensin 2 (Ang II), endothelin 1 (ET-1) and phenylephrine (PE)) interacts with alpha 
adrenergic receptors and activates both Gαq/Gα11 and its downstream signalling 
proteins, including phospholipase C (PLC), MAPKs (Ras-MEKK-MEK-ERK1/2), protein 
kinase C (PKC), protein kinase A (PKA) and Ca2+/calmodulin-dependent protein kinase 
[22]. It has been shown that in animal models harbouring a double heart specific 
knockout for Gαq/Gα11, the cardiac hypertrophic phenotype or activation of the foetal 
gene program in response to aortic banding is completely blunted [23], supporting the 
cardinal role of this pathway in the development of pressure overload-induced cardiac 
hypertrophy. Consequently, agonist stimulation of all these three receptors is sufficient 
to induce strong CM hypertrophy [24].   
ANGII is the principal vasoactive peptide of the renin-angiotensin system. It exerts 
multiple pathophysiological effects in the cardiovascular system, at both endocrine and 
paracrine level, including vasoconstriction, aldosterone release and regulation of cell 
growth [25]. ANGII acts through two specific and different alpha adrenergic receptors, 
namely AT1 (two isoforms are present in rodents AT1A and AT1B) and AT2 [26]. Both 
receptors are expressed in the heart; nevertheless, only AT1 transgenic mice developed 
pathological hypertrophy and die prematurely of heart failure, whilst AT2 transgenic 
mice do not show any specific cardiac phenotype [27] [28]. Conversely, both cardiac 
specific AT1- and AT2- KO mice showed a blunted hypertrophic phenotype in pressure 
overload-induced hypertrophy. Furthermore, Zou et al. [29] have shown that AT1 
receptors can sense and transduce mechanical stress even in absence of ANGII thus 
underlying the involvement of Gαq/Gα11 and MAPKs in mechanotransduction. In 
addition, it has been shown that both ANGII and Mechanical stretch activates PKC [30] 
[31] and that specific PKC isozymes are increased in several in vivo models of cardiac 
hypertrophy  [32] [33]. The heart expresses different PKC isozymes, namely  α-, β-, δ-, ε-, 
η-, and ζ-PKCs [34]. In particular, εPKC and δPKC have been reported to be activated in 
response to hypertrophic stimuli in cultured myocytes and their overexpression and 
activation in vivo induced a physiological form of cardiac hypertrophy, thus suggesting 
a common role in regulating adaptive CMs-hypertrophy [33]. Conversely, mice treated 
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with a εPKC - selective inhibitor showed LV-dilation, heart failure and death [33]. The 
expression β PKC is characteristics of the foetal stages of heart development and its 
expression is augmented during pathological cardiac remodelling and heart failure. 
Accordingly, β PKC overexpression and activation leads to pathological cardiac 
hypertrophy and fibrosis with increased expression of ANP and βMHC, known markers 
of detrimental cardiac remodelling [34]. Even though specific inhibitors of βPKC 
prevented hypertrophy in mouse model of constitutively active β PKC, pressure 
overload induced hypertrophy was not blunted in a mouse model of βPKC knock out, 
thus suggesting that β PKC is not a key-player in pressure-overload induced cardiac 
hypertrophy.  
Phenylephrine (PE) is an α 1-adrenergic receptor agonist, which elicits hypertrophic 
effects in CMs via Gαq/Gα11 activation [35]. The hypertrophic phenotype induced by PE 
on NRVCs and ARVCs is mainly sustained by the overall increase in protein synthesis 
[35]. This effect is due to the activation of Erk, which phosphorylates the ribosomal S6 
kinase 1 (S6K1) and the eukaryotic translation initiation factor 4E-binding protein 1 (4E-
BP1) [35]. Phosphorylated S6K1 promotes the translation of mRNAs for components of 
the translation machinery while phosphorylated 4E-BP1 cannot sequester eIF4E thus 
promoting the formation eIF4E/eIF4G complex with the recruitment of ribosomes to the 
mRNA [35]. The effects of PE on S6K1 and 4E-BP1 are completely blunted by MEK 
inhibitors and partially inhibited by rapamycin (an mTOR blocker), this implying a 
convergence between mTOR and MEK-dependent signalling pathways [35].  
Gs signalling 
β-adrenergic receptor stimulation by catecholamines, namely adrenalin and 
noradrenalin, represents the most important regulatory mechanism for cardiac 
performance, and it works through a Gs subunit.   
In particular, after an acute- (myocardial infraction) or a chronic- (hypertension) insult to 
the myocardium, there is an increase in sympathetic nervous system activation and 
consequent increase in catecholamine production, which may promote pathological 
cardiac remodelling and lead to heart failure, arrhythmia and eventually death [36].  
Reduction of an excessive and prolonged activation of β -adrenergic receptors by β -
blockers improves cardiac function and stands as one of the most effective therapeutic 
interventions in patients with HF [37, 38]. Moreover, β -blockers exert other beneficial 
effects, including reduction of heart rate, decrease of blood pressure, inhibition of the 
renin-angiotensin system and reduction of atrial and ventricular arrhythmias [38].   
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The human heart expresses three β -adrenergic receptor (β-AdR) subtypes: β1, β2 and 
β3. In the healthy human heart, the stimulation of β1- and β2-AdRs leads to inotropic 
and chronotropic effect on CMs whilst the effect of β3-adrenergic activation is reported 
to decrease cardiac contractility. The role of the β3 -AdR, however, still remains not 
completely understood. 
β1- and β2-AdRs are the most abundant in the heart and are expressed at a ratio of 7:3. 
In humans, both β1 and β2 subtypes are both coupled to a Gs-type of G protein, which 
in turn activates adenylate-cyclase (AC) and, consequently, PKA. Activated PKA 
phosphorylates key proteins for cardiac function, namely L-type calcium channels, 
phospholamban, troponin-I (TPNI), ryanodine receptor2 (RYR2), myosin binding 
protein-C (MyBP-C) and protein phosphatase inhibitor-I [39]. This influences CM 
contractile activity by augmenting Ca2+ influx and reuptake into the sarcoplasmic 
reticulum, and modulating myofilament Ca2+ sensitivity [39].  In contrast, GS activation 
by β2-agonist in vascular smooth muscle cells (vSMCs), leads to vSMCs relaxation due to 
the cAMP-dependent inhibition of myosin light chain kinase that is responsible for the 
phosphorylation of smooth muscle myosin [40].  It is also important to underline that 
Cardiac fibroblast (CFs) contain G protein-coupled signalling systems that are distinct 
from those of cardiac myocytes [41]. In particular, β2receptors links Gs with a peculiar 
Gq/Gs cross talk phenomenon associated with little or no coupling to Gi, thus 
distinguising the signaling in CFs from that in myocytes [41]. 
 However, β2 -AdR-induced production of cAMP has been characterized in CMs, 
depending on species, as undetectable or highly localized in contrast to β1 -AdR-
induced-production that homogenously elevates cAMP in all the cells [39, 42, 43].  Not 
only cAMP production is highly localized under β2 -AdR stimulation, but also the β2 -
AdRs themselves show a different sub-cellular compartmentalization compared to β1-
AdRs. 
In CMs, β2-AdRs are localized in the sub-sarcolemmal region in close proximity to L-type 
calcium channels and tend to be embedded into CM’s caveolae together with their 
effectors AC and PKA [44]. These compartments function as a separate signalosome, 
thus defining the spatial activation of β2 -AdRs [44]. This evidence is in general 
agreement with the observation that, in frog CMs, in which the β2 -AdR subtype is 
predominant, stimulation by the β2-AdR agonist isoproterenol applied to one extremity 
of the cell is not effective on remote L-type calcium channels [45]. 
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Considering the fact that both PKA active subunits and cAMP are readily diffusible, 
another mechanism must be involved in the local control of the β2-AdR/PKA axis, such 
as transduction pathways that inhibit cAMP/PKA activity. In accordance, it has been 
shown that treatment of ventricular rat CMs with pertussis toxin (PTX), a potent 
inhibitor of Gi subunits, significantly potentiate β2 -AdR-mediated inotropic effects 
closely resembling the β1 -AdR effect [46]. These results collectively indicate that β2 -
AdR/Gi coupling improves the functional compartmentalization of β2 -AdR/Gs-PKA 
signalling in ventricular rat CMs.  
Accordingly, the transgenic overexpression of the β1-AdR in mice is detrimental, since it 
determines an increase in cardiac contractility at a young age that evolves into a 
marked CMs hypertrophy associated with progressive HF with functional and 
histological abnormalities [47].  
Conversely, the effect of the overexpression of β2 -receptor is closely related to the 
amount of receptor produced; on the one hand, low-level (30-fold over expression) of 
β2-receptor improves cardiac contractility in transgenic mice overexpressing Gq/G11 
(Tg-Gq/G11); on the other hand, high-level (350-fold over expression) are detrimental in 
pressure-overload hypertrophy and Tg-Gq/G11 mice, whilst beneficial in restoring 
cardiac contractility in a mouse model of myocardial infarction. On the contrary, two 
large-scale retrospective analyses regarding the effect on the use of β2 -agonists in 
patients with chronic obstructive pulmonary disease (COPD)  reported increased rate of 
hospitalizations for HF as well as increased risk of mortality in patients with left 
ventricular dysfunction [48] [49]. This can be also partially explained by the fact that 
apart from the effect on cardiac contractility, β -AdR-stimulation induces also a 
remarkable CMs hypertrophy both in vitro and in vivo.  By studying of the effect of the 
β-AdR-agonist isoproterenol (ISO), emerged that the ISO-induced stimulation of β-AdRs 
evokes the Raf1-MEK1-ERK1/2 pathway. In particular, the pre-treatment of cells with 
specific PKA inhibitors  (Gs signalling) as well as PTX (Gi inhibitors) completely blunts 
the activation of ERK1/2 by ISO, thus suggesting that the pro-hypertrophic effect 
dependent on β -AdRs agonist is dependent on activation of ERK1/2 by both 
Gs/cAMP/PKA an Gi/Src/Ras pathways. 
Gi signalling 
Both cardiac muscarinic and β2 -adrenergic receptors couple with inhibitory signal-
transducing G protein-i (Gi) to inhibit AC and directly oppose Gs-dependent signalling 
(reviewed in [17]). In human ventricular myocardium, Giα2 and Giα3 (Giα splice variants) 
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mRNA are the predominant Giα mRNA subtypes [50]. In CMs, settings of induced Gi 
correlate with reduced PKA activity and with constitutively active phospholamban, 
leading to prolonged inhibition of the sarcoplasmic reticulum calcium pump (SERCA2a), 
so contributing to impaired ventricular pump function [51, 52]. Moreover, NRVCMs 
treated with ISO showed a pro-hypertrophic phenotype characterized by the activation 
of the Raf1-MEK1-ERK1/2 pathway in a Gi dependent manner; the βγ  subunit of Gi 
protein activates ERKs through the Src/Ras tyrosine kinases pathway. Of note, both Giα2 
and Giα3 mRNA levels were found up-regulated in left ventricular myocardium from 
failing hearts and Inhibitory signal-transducing Gi was also found to play an important 
role in the development of severe arrhythmia and heart failure [51].  
1.5.2.1.2 Calcineurin-NFAT pathway 
The calcineurin-NFAT pathway plays a crucial role in the pro-hypertrophic signalling. 
The serine-threonine phosphatase calcineurin is expressed in multiple tissues and 
consists of two subunits: CnA, which is the catalytic domain (it exists in three different 
isoforms, CnAα, CnAβ and CnAγ) and CnB, which is regulatory [53]. In the presence of 
high levels of Ca2+, calcineurin binds with calmodulin and dephosphorylates 
transcription factors of the NFAT (nuclear factor of activated T-cells) family, thus 
allowing translocation of these factors into the nucleus [53] [54]. Activated NFAT3 
interacts with the cardiac zinc-finger nucleases GATA4, resulting in increased expression 
of genes associated with cardiac hypertrophy [55]. Due to its dependence on Ca2+  
levels, the calcineurin-NFAT pathway is activated also under ANGII and PE stimulation, 
which both activate PLC leading to an increase of Ca2+ cytosolic levels [55].  
Accordingly, the calcineurin inhibitors cyclosporine A (CsA) and FK 506, which form 
cytoplasmic immunophilin complexes that are potent calcineurin inhibitors, completely 
blunted hypertrophy induced  by both PE and ANGII in neonatal rat ventricular CMs 
[55]. 
The effect of CsA and FK 506 was further validated as an effective treatment in 
preventing cardiac hypertrophy in Tg mice carrying a constitutive form of CnA, which 
are known to develop a massive cardiac hypertrophy [55]. 
Moreover CsA and FK 506 were shown to counteract hypertrophy in different Tg models 
such as cardiac specific overexpression of tropomodulin (TOT mice), cardiac specific 
mutant form of myosin light chain 2v (MLC2v), cardiac specific overexpression of β -
tropomyosin as well as in a rat model of pressure overload [56]. 
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Collectively, this evidence suggests that calcineurin might be involved in most, if not all, 
aetiologies of pathological cardiac hypertrophy, thereby representing an attractive 
therapeutic target for prevention, and perhaps treatment, of this pathological 
condition. 
1.5.2.1.3 MEF2/HDAC and chromatin remodelling 
Chromatin remodelling plays an important role in the alteration of gene expression 
during cardiac hypertrophy, mainly thanks to the activity of histone deacetylases 
(HDACs) and histone acetyl transferase (HATs) (reviewed in [57]).  
In particular, HATs promote gene activation by acetylating nucleosomal histones, 
thereby relaxing chromatin structure [58].  On the contrary, HDACs, which deacetylate 
histones, induce chromatin condensation and consequent transcriptional repression 
[58]. In physiological conditions, class II HDACs (HDAC4, HDAC5 and HDAC9) were 
shown to inhibit activity of MEF2, a transcription factor known to be involved in the 
transduction of pro-hypertrophic stimuli and the cosequent cell growth [59]. Under pro-
hypertrophic stimuli such as pressure overload and calcineurin activation, class II HDACs 
are phosphorylated by specific kinases, which inhibit their association to MEF2A and 
thus blunt the protective effect of HDACs against cardiac hypertrophy [59]. Accordingly, 
Tg mice with a double cardiac specific KO of HDAC9 (the class II HDAC most expressed 
in cardiac tissue) showed an age-dependent hypertrophic cardiac phenotype and 
increased sensitivity to cardiac pressure overload [59]. The identities of cardiac HDAC 
kinases have remained unclear; nevertheless it has been shown that phosphorylation of 
HDAC5 by protein kinase D (PKD), a downstream effector of PKC, drives nuclear export 
of class II HDAC5 in CMs [60]. Accordingly, inhibition of PKC and PKD prevents nucleo-
cytoplasmic shuttling of HDAC5 in response to a subset of hypertrophic agonists [61]. 
These findings collectively support a novel function for the PKC/PKD axis in coupling 
extracellular cues to chromatin modifications that control cellular growth. 
In contrast,  pharmacological  treatment of mice with non selective (trichostatin A and 
valproic acid) or HDACI-selective (SK-7041) inhibitors almost completely block cardiac 
hypertrophy induced by isoproterenol, ANGII and pressure overload after 2 weeks of 
pressure overload [62]. Even if the inhibition of type II HDACs promotes cardiac 
hypertrophy, the overall effect, observed in pharmacological non selective inhibition of 
HDACs, reflects the higher activity of type I HDACs compared to type II HDACs  [62].  
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1.5.2.2 Signalling pathways involved in physiological hypertrophy 
1.5.2.2.1 PI3K-Akt  
Insulin-like growth factor 1 (IGF1) receptor signalling 
Insulin-like growth factor 1 (IGF-1) plays an essential role in normal foetal and postnatal 
growth and development [63]. IGF1 is also produced by the heart and binds to a cell 
surface receptor, insulin-like growth factor 1 receptor (IGF1R), a tyrosine kinase receptor 
that in turn activates the phosphatidylinositol-3-kinases (PI3Ks). PI3Ks are a family of 
enzymes that have been linked to a diverse group of cellular functions, particularly cell 
growth, survival, differentiation, proliferation and cell trafficking [64]. 
Transgenic mice expressing human IGF1 under the α-skeletal actin promoter (SIS2 mice) 
developed cardiac hypertrophy, which was associated with a short-term increase in 
cardiac function [65]. However, the prolonged cardiac specific overexpression of IGF1 
was associated with systolic dysfunction [65]. Due to the cardiac specific overexpression 
of IGF1, SIS2 mice showed low serum levels of IGF1 but long-term expression was 
associated with increases in gut, liver and spleen weight, suggesting undesired systemic 
effects related to IGF1 over-expression. 
In 2004, McMullen et al. [66] generated a transgenic mouse model that overexpressed 
IFG1R under the control of αMHC. Interestingly, these IGF1R-Tg mice showed cardiac 
hypertrophy (proportional increase of all chambers and ventricular wall thickness), 
increased CM area, and enhanced systolic function up to 16 month of age, overall 
displaying a phenotype similar to Tg-mice expressing a constitutive active variant of 
PI3k (caPI3K) [66] [67]. Furthermore, these animals did not show any sign of 
cardiomyopathy, such as necrosis, fibrosis, or myocyte disarray at histological analysis 
[66]. 
 At the molecular level, the PI3K pathway was increased in IGF1R-Tg mice, while no 
activation of the MAPK pathway or calcineurin was detected [66]. In addition, IGF1R-Tg 
mice developed less interstitial fibrosis in the TAC model, suggesting a protective effect 
of IGF1 in a setting of pressure overload-induced hypertrophy [66]. Notably, these 
features of physiological hypertrophy were completely blunted in the dominant-
negative-PI3K mutant, suggesting a model in which IGF1 induces compensated 
hypertrophy in a PI3K-dependent manner [66].  Moreover, this evidence was confirmed 
in two additional, more recent studies using mice with muscle-specific knockout of the 
p85α/p55α/p50α and p85β(global) regulatory subunits of PI3K [68] or cardiac-specific 
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ablation of p110α [69]. These mice showed a decrease in heart weight-to-body weight 
ratio of approximately 20% and 16%, respectively [68, 69], similar to what reported by 
Shioi T. et al. [67]. In addition, similar to what was observed in the CM-specific knockout 
of IGF1R [70], dnPI3K mice also exhibited a reduced hypertrophic response to exercise.  
A well characterized target of PI3K is Akt, a serine/threonine kinase (also known as 
protein kinase B), which belongs to a family of proteins, including 3 different isoforms 
(Akt1, Akt2 and Akt3), each encoded by a different gene [71]. Only Akt1 is highly 
expressed in the heart [71]. Akt knockout mice revealed that Akt1 is required for 
physiological, rather than pathological, heart growth, as these mice showed a reduced 
hypertrophic response to exercise but not to pressure overload [72], also in agreement 
with the phenotype of mice with reduced PI3K [73]. It is now generally accepted that 
Akt1 mediates cardiac cell growth, whereas Akt2 is important for cardiac metabolism 
[74] [72].  In mice, the selective cardiac overexpression of a constitutively active mutant 
of Akt (E40K mutant) under the control of the αMHC promoter produced a concentric 
LV hypertrophy with a significant increase in CM cell size whilst inducing a remarkable 
inotropic effect [75]. Moreover, it was shown that Akt induces cardiac hypertrophy in 
vivo by activating the glycogen synthase kinase-3 (GSK3)-GATA4 pathway [75]. 
GSK3 also exists in different isoforms (GSK3α and GSK3β), which are both expressed in 
the heart, where they play different roles. Phosphorylation of GSK3α induces a 
compensatory response reducing hypertrophy through the inhibition of ERK, as shown 
by knock-in mice harbouring a mutated GSK3α insensitive to Akt phosphorylation, 
which exhibit severe cardiac dysfunction and heart failure [76]. In contrast, 
phosphorylation of GSK3β is essential for the development of pathological hypertrophy, 
as GSK3β knock-in mice, similarly expressing a mutated protein insensitive to Akt 
phosphorylation, maintain LV function after TAC, despite suppression of hypertrophy 
[77].  
1.5.2.2.2 Thyroid hormone receptor signalling 
The thyroid gland secretes two biologically active hormones: T3 (3,5,3ʹ­triiodothyronine) 
and T4 (3,5,3ʹ,5ʹ­ tetraiodothyronine; also known as thyroxine), although T4 is often 
converted into cells in T3, which is the molecular active molecule, by the enzyme 5’-
deiodinases (reviewed in [78]).  
 Thyroid hormone exerts a large number of activities in the cardiovascular system 
involving both cardiac contractile effects and cardiac remodelling (reviewed in [78]). 
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These effects are exerted mainly through three ways: by directly binding its cognate 
nuclear receptor in cardiac cells (thyroid hormone receptor­α is highly expressed in the 
heart) and consequent up-regulation of target genes mediated by binding of the 
activated receptor to the thyroid hormone response element (TREs); by regulating ion 
channels in the CM cell membrane; and through systemic effects of T3 and T4, which 
determine modulation of cardiovascular haemodynamic and cardiac filling (reviewed in 
[78]). 
In CMs, the speed of relaxation is mainly dependent on the reuptake of calcium into the 
sarcoplasmic reticulum by SERCA2a, the calcium ATPase of the sarcoplasmic reticulum, 
the activity of which is negatively regulated by phospholamban [79]. Thanks to three 
TREs present in its promoter, the transcription of the Serca-2a gene is regulated by 
thyroid hormone [80]. The expression of phospholamban is also dependent on the 
levels of thyroid hormone, as shown by its up-regulation in patients with 
hypothyroidism [81].  Taking this evidence together, thyroid hormones regulate CMs 
contraction rate by the regulation of the Ca2+-ATPase/phospholamban pump ratio. 
An additional cardiac effect of the thyroid hormone occurs immediately after birth, 
when it switches on transcription of the myosin heavy chain α (αMHC) and inhibits the 
expression of βMHC [82].  
The pro-hypertrophic effect of T3 in cultured CMs is mainly driven by the PI3K-AKT-S6K 
cascade [83]. Accordingly, the effect of T3 hormone on cultured CMs is completely 
inhibited by PI3K inhibitors as Wortmannin or LY294002 [83].  Furthermore, co-immuno-
precipitation studies have shown a direct interaction between the cytosol-localized 
thyroid hormone receptor alpha-1 (TRα1) and the p85α subunits of PI3k [83], thus 
supporting the existence of a non-genomic response to T3 hormone based on 
cytosolic-localized TRα1 [83].  
1.5.3 Murine models of cardiac hypertrophy 
There is a wide range of different genetic and non-genetic animal models of cardiac 
hypertrophy. The most relevant genetic models, including transgenic, knock-in, 
knockout and dominant negative (dn) animals, are described in section 1.5.1 in the 
context of the description of the main pathways involved in cardiac hypertrophy. In 
addition, pharmacological modulation of known intracellular signalling pathways 
involved in pathological cardiac hypertrophy is widely used in order to obtain a more 
tunable phenotype and to avoid embryonic lethality, which may occur in transgenic 
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models.  Among all pharmacological models it is worth to mention the mouse and rat 
model of ANGII-induced cardiac hypertrophy. It has been shown in adult rat that a 
continuous infusion of ANGII (200ng/kg/min) produced a clear hypertrophic phenotype, 
characterized by reactivation of the foetal genes, increase in LV-mass, and cardiac 
fibrosis [84]. Moreover, as mentioned in section 1.5.2.1.1, AT1 receptor plays also a 
pivotal role in the stretch-dependent hypertrophic response in a mouse model of 
pressure-overload, thus eliciting the ANGII-induced cardiac hypertrophy model as an 
alternative and less-invasive model then TAC-induced pressure overload.  Big efforts 
have been done in the last years to elucidate the direct effects of ANGII on cardiac 
myocytes and cardiac fibroblast independent of secondary hemodynamic and neuro-
humoral effects due to renin-angiotensin system (RAS) activation. On the one hand, 
ANGII exerts its trophic effect by activating MEK/ERK/p70S6 cascade thus inducing an 
increase in protein synthesis and a consequent increase in CMs cell size. Accordingly, 
the hypertrophic response of CMs exposed to ANGII and treated with PD98059, a 
selective inhibition of ERK1/2 activity, was completely blunted [85]. On the other hand, 
ANGII upregulates TGF-β1 expression via activation of the angiotensin type 1 (AT1) 
receptor in cardiac myocytes and cardiac fibroblasts, thus leading to cardiac fibroblast 
proliferation, increased collagen deposition [86]. 
In addition to these genetic models, physical procedures can be applied to induce 
physiological or pathological hypertrophy, such as exercise and aortic banding 
(transverse aortic constriction). 
 
1.5.3.1 Transverse aortic constriction 
Transverse aortic constriction (TAC) as a mouse model of pressure overload induced 
hypertrophy, was first described by Rockman H. A. et al. [87].  
Aortic banding is a widely used method to induce left ventricular (LV) hypertrophy in 
mice and mimics human aortic stenosis with development of pressure-overload-
induced LV hypertrophy [87]. Alternative sites for aortic constriction include the 
ascending and abdominal aorta. On the one hand ascending aortic constriction 
provides a stronger LV-overload. On the other hand, abdominal aortic constriction 
leaves intact a larger portion of the circulation as a means of possible compensation 
(reviewed in [88]). The ascending aortic banding is usually preferred providing a more 
direct and rapid source of pressure overload on the LV with a significant degree of 
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hypertrophy already after 48 h (reviewed in [88]). In order to reproduce this artificial 
stenosis, a wire with a snare on the end is passed under the aorta between the origin of 
the right innominate and the left common carotid arteries. A silk suture is snared with 
the wire and pulled back around the aorta (reviewed in [88]). Then a gauge needle is 
placed next to the aortic arch, the suture is snugly tied around the needle and the aorta, 
and following ligation the needle is quickly removed (reviewed in [88]).  
As mentioned in section 1.5.2.1, angiotensin type 1 (AT1) receptors and the associated 
Gαq/Gα11 proteins play a critical role in transducing stretch-associated stress signals in 
pressure overload-induced hypertrophy; accordingly, a double heart specific knockout 
for Gαq/Gα11 completely blunts aortic banding induced hypertrophy [23]. Interestingly, 
the work of Kebir S. et al. reports a massive mis-localization of intercalated disk (ID)-
associated proteins in mice submitted to pressure overload-induced [89]. This finding 
suggests that TAC-induced hypertrophy not only induces the activation of pro-
hypertrophic genes at the transcriptional level via the AT1 receptor but also induces 
massive remodelling of IDs, thus impairing the myocardial functional syncytium. 
1.5.3.2 Exercise induced hypertrophy 
Exercise-induced cardiac hypertrophy occurs following aerobic endurance exercise and 
is considered a physiologically beneficial adaptation [90]. A robust experimental model 
to mimic the training response in humans is the model of exercise training in laboratory 
animals. The exercise can follow different protocols: treadmill, voluntary and swim 
training. Different treadmill protocols have been developed involving different 
duration, intensity, frequency, speed and with different range of treadmill inclination 
[90]. Interval treadmill training program, involving high-intensity running bouts and 
progressive increased exercise load, has been shown to induce observable hypertrophy 
within 4 weeks and resulted in 25-35% increased ventricular weight with increased CM 
dimension [90]. This protocol was reported to be the most effective among the 
treadmill variants.  
Voluntary wheel program has also been reported to induce robust physiological 
hypertrophy, leading to a complete hypertrophic phenotype in 3-4 weeks of training.  
The swim program appears to be equally effective as treadmill or voluntary wheel to 
induce physiological hypertrophy [90]. The duration of swim applied varies 
considerably, from 1-6 hours/day and 1-24 months; it is now accepted that the duration 
and magnitude of response are not directly proportional [90]. 
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1.6 Heart failure 
The American Heart Association/American College of Cardiology guidelines define HF 
as a complex clinical syndrome that can result from any structural or functional cardiac 
disorder that impairs the ability of the ventricle to fill or eject blood” [91] [92]. This 
syndrome scores more than 26 million cases worldwide, of whom 74% suffer at least 1 
comorbidity, which is considerably worsened by HF [93]. Due to the complexity of the 
HF pathophysiology together with the high number of causes that can lead to the 
development of this condition, a standard criteria used to distinguish between systolic- 
and diastolic-HF is the Left Ventricular Ejection Fraction that can respectively be 
preserved in the case of systolic-HF (EF≥40%; HFpEF) or reduced in the case of diastolic-
HF (EF≤40%; HFrEF).  Current therapies for HFrEF are effective and can count on several 
classes of chemical compound, including angiotensin aldosterone system-inhibitors, 
beta-blockers, statins and, very recently, LCZ696 (neprilysin pathway inhibitor) [94].  
Clinical trials based the above-mentioned drugs for the treatment of HFpEF have insted 
been ineffective in showing benefit, with the exception of a small study evaluating 
statins effect on 185 patients; however, a working-mechanism for statins in this 
condition is still missing [95]. The number of patients with HFpEF is growing year by 
year thus inevitably raising the claim for the development of novel therapeutic 
approaches for compensated HF. 
1.6.1 Heart failure with preserved ejection fraction (HFpEF) 
HFpEF currently accounts for 50% of all cases of HF with a higher incidence in women 
then man; the prevalence of this form relative to HFrEF is growing by 10% per decade 
[96, 97]. This trend is sustained by the increasing rate of HFpEF-associated comorbidities 
(hypertension, obesity, average increased life-span) together with the availability of 
effective therapies for patients with HFrEF, as reported above [94].  
HFpEF pathophysiology is complex and several stages become apparent in the range 
between asymptomatic and symptomatic HFpEF, including systemic inflammation, LV 
hypertrophy, slow LV relaxation, LV diastolic stiffness, decreased LV systolic 
performance, left atrial remodeling, peripheral vascular resistance, impaired epithelial 
function, increased pulmonary arterial and venous resistance, neurohormonal 
activation and ventricular-arterial coupling [98].  Although there is not a widely 
accepted definition of HFpEF yet, a combination of three main conditions are 
considered as required to diagnose HFpEF: 1) signs and symptoms of HF, 2) conserved 
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or slightly reduced EF with no LV dilation; 3) relevant LV remodeling associated with 
hypertrophy and diastolic dysfunction [99].  
Up to now, there are two main pathophysiologic theories about the progressive 
maladaptive process leading to HFpEF. One theory, originally suggested by Borlaug and 
Kass, attributes a pivotal role to an increase in LV-stiffness, which impairs LV-relaxation 
and contributes to a dramatic increase in LV-filling pressure, eventually evolving into 
diastolic dysfunction and incident HFpEF. An alternative theory by Paulus and Tschope 
suggests that multiple comorbidities (obesity, diabetes, hypertension) induce a pro-
inflammatory state; this shifts the paradigm of HFpEF-onset from pathological LV-
overload to coronary micro vascular inflammation [100].  
In accordance with the model proposed by Borlaug and Kass, the passive force of single 
CMs, isolated from patients with diastolic-HF (dHF), is higher compared to patients with 
systolic-HF (sHF), suggesting an increased CMs stiffness.  
The major known regulator of CM stiffness is Titin. This very large protein exists in three 
major isoforms, which are the result of different spicing events: 1) the adult N2B is the 
shortest form and results in the highest stiffness; 2) the N2BA is longer and provides a 
medium level of stiffness; 3) N2BA foetal form is the longest and most compliant. Titin 
elasticity can be regulated both by isoform relative expression (increased N2B/N2BA 
ratio results in increased stiffness) and phosphorylation (hypo-phosphorylation of the 
N2B domain results in increased stiffness) [101] [102]. N2B has also been described to 
bind the scaffolding protein four and half lim domain 1 (FHL1) [103]. FHL1 senses cell 
stretch via the N2B domain and is responsible for Gq-induced activation of the MAPK 
cascade in pressure-overload-induced hypertrophy [103]. Furthermore, FHL1 double KO 
mice showed increased LV-diastolic-compliance in TAC-induced hypertrophy [103]. 
These observations suggest the critical importance of a better understanding in the role 
of Gq/MAPK-FHL1-Titin axis in diastolic heart failure. 
1.6.2 Murine models of HFpEF 
The major contributor to HFpEF development is hypertension, which also represents a 
major risk factor for coronary heart disease [97]. Dahl-salt-sensitive rats are an inbred 
strain that develops hypertension (systolic blood pressure ≥175 mm Hg) when fed with 
a high-salt diet (8% NaCl), leading to LV-hypertrophy and  HF [104]. These rats if started 
on a high-salt diet at 7 weeks eventually develop HFpEF by 19 weeks [105] and present 
signs of HFpEF including tachypnea, lack of activity and pulmonary oedema (confirmed 
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post mortem by increased lung weight) [105].  Conversely, Klots S. et al. reports that 
Dahl-salt-sensitive rats show only a slight increase in end-diastolic pressure volume 
relationship (ENDPR), which become undistinguishable when LV-dilation appears  [106]. 
Obese diabetic Zucker rats, which do not develop increased LV-mass whereas diastolic 
dysfunction is evident, have recently been crossed with Dahl-salt-sensitive rats 
generating the Dahl/SS/obese rats, which show LV-hypertrophy, LV-diastolic-
dysfunction and cardiac fibrosis [107]. This model is of particular interest since diabetes 
is one of the most frequent comorbidities In patients with HFpEF. 
HFpEF can also be effectively induced in mice. C57bl6 mice treated for 4 weeks with 
subcutaneous infusion of ANGII develop diastolic dysfunction with conserved EF 
(decreased  E/A ratio, decrease dP/dTmax and prolonged LV-relaxation time), whereas 
no evidence of increased lung weight has been reported [108] [109].  
 
1.7 MicroRNAs in cardiac remodelling 
1.7.1 Biology of microRNAs 
MicroRNAs are small, highly conserved, approximately 21‐mer RNA molecules that 
regulate the expression of genes by binding the 3'‐untranslated regions (3'‐UTR) of 
specific mRNAs in the process of RNA interference (RNAi) (reviewed in ref. [110]). These 
regulatory molecules are produced by the processing of long RNA transcripts, referred 
to as primary microRNAs (pri-microRNAs), which form stem‐loop structures [110]. These 
are further processed in the nucleus by the Microprocessor, containing Drosha (RNase III 
enzyme) and DGCR8 (dsRNA‐binding protein), allowing formation of pre‐microRNAs, 
short stem‐loop structures of 65–75 nt. Finally, after export into the cytoplasm by the 
exportin V protein, a further complex including the RNase III Dicer produces the mature 
microRNA [110]. The leading strand of the microRNA is loaded onto the RNA‐induced 
silencing complex (RISC) in order to silence the target mRNA through sequestration, 
translational repression or mRNA degradation [111] (Figure 4). Unlike the process 
involving siRNAs, microRNAs do not require perfect pairing to induce silencing, and are 
therefore expected each to control expression of several tens or hundred different 
cellular genes.   
Several thousand microRNAs have been identified and sequenced so far; to date, the 
largest searchable online repository for published microRNA sequences and associated 
annotations is miRBASE. The latest release of this database (miRBASE version 21) 
 29 
contains 28,645 entries representing hairpin precursor microRNAs, expressing 35,828 
mature microRNA products, in 223 species (see www.mirbase.org).  
The sequences of many microRNAs are homologous among organisms, suggesting that 
microRNAs represent a relatively old and relevant regulatory pathway (reviewed in ref. 
[112]). Taken together these evidences , it is becoming evident that the role of 
microRNAs in regulating gene expression in higher eukaryotes could be as important as 
that of transcription factors, with the advantage that they are relatively limited in 
number, thus facilitating any screening strategy.  
 
1.7.2. microRNA-mediated mechanisms of mRNA degradation 
MicroRNAs control post-transcriptional gene expression by three main mechanisms: 
1) triggering an endonuclease cleavage; 
2) accelerating mRNA decapping, thus increasing mRNA decay; 
3) promoting translation repression. 
A perfect base pairing between microRNA and targeted mRNA generally improves 
endonuclease cleavage even though it is not per se sufficient, and some mismatches 
are still allowed for an efficient cleavage of the targeted transcript. This shows that there 
are additional requirements for a RISC complex to catalyse endonucleolytic cleavage 
[113, 114]. The microRNA determined endonuclease cleavage is generally referred to as 
“slicer” activity and was first described in mammal cells by Tuschl et al. in 1999 [115] and 
further confirmed in both plants and metazoans [113, 116]. Even though the complete 
picture of the determinant requirements for “slicer” activity is still missing, it has been 
shown that Argonaute-2 (AGO2), a protein which is part of the RISC complex, is the only 
one of the four mammalian Argonaute (AGO) proteins capable of directing 
cleavage[117]. The requirement for a specific AGO protein for endonuclease cleavage 
suggests that a specific microRNA, which preferentially assembles with an alternative 
AGO protein, might be unable to direct cleavage, even if the microRNA/mRNA base-
pairing is perfect. 
 In addition, several experimental evidences suggest the possibility that microRNAs also 
target mRNAs for increased decay by a “slicer-independent” mechanism [118]. 
Accordingly, all four versions of the mammalian AGO proteins co-immunoprecipitate 
with the decapping enzyme DCP1 [119], and in both mammals and nematodes these 
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proteins are mainly concentrated in specific cytoplasmic foci known as P-bodies, which 
can be considered hot-spots of mRNA decapping and degradation [120]. 
A third way that microRNAs silence mRNAs is by interfering with their translation. The 
first evidence was reported in 1993 by the fact that the lin-4 microRNA reduced the lin-
14 protein with no changes in lin-14 mRNA levels [121]. There are now several examples 
where protein-silencing by a microRNA is observed with either no change in the mRNA 
level, or only a slight decrease in mRNA levels [122-124]. The ability to repress 
translation is thought to be common to all members of the AGO family of proteins. For 
example, tethering of either human AGO2 or AGO4 to a target mRNA can lead to 
translational repression[125], even though translational repression in response to 
microRNAs remains intact only in AGO2-null cells, thus suggesting a more direct 
involvement of the other members of AGO2 family in microRNA-mediated translational 
repression. 
Different approaches have been employed so far to identify microRNA targets such as 
bioinformatic-based prediction algorithms, mRNA sequencing (mRNA-Seq), RNA cross-
linking and AGO2-IP followed by mRNA sequencing (RIP-Seq) and quantitative 
proteomics (SILAC). All these approaches lead to the identification of several hits that 
must be further validated with both 3’UTR-reporter assay, using mutated or WT variants 
of the predicted binding sites, and WB analysis against the targeted proteins. 
The bioinformatic-based approach is fast and cheap, however it generates too many 
false-positive predictions of microRNA targets. On the one hand the major limitations of 
transcriptomics-based methodologies is that changes in protein abundance are missed; 
on the other hand quantitative proteomics can be considered a complementary 
technology to integrate the information generated by mRNA-Seq analysis after 
microRNA over-expression or inhibition (reviewed in [126]). 
 
 
1.7.3. Heart biology and microRNAs 
The crucial role of different microRNAs in cardiac development, hypertrophy and heart 
failure has been extensively investigated (reviewed in ref. [127]).  In particular, it was 
shown that microRNAs are fundamental for the correct cardiac development and the 
ablation of the whole microRNAs network by the knock-out of DICER, in both the 
developing and adult heart, leads to severe heart failure and death [128]. Furthermore, 
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many studies of gain- and loss-of-function have highlighted microRNA families or single 
microRNAs involved in pathological cardiac remodelling, raising the possibility to use 
these microRNAs as either biomarkers or targets for novel therapies [129], [130]). Several 
microRNAs have been described that regulate specific processes in cardiac biology, 
including CM proliferation (miR-1 [131], miR-133a [132], miR-199a-3p [133]), CM 
hypertrophy (miR-1[134], miR-133 [135], miR-195 [136], miR-199b [137], miR-212/132 
family [138], miR-378 [139], miR-23a [140]), cardiac fibrosis (miR-29 [141], miR-21 [142] 
and CMs contractility (miR-208a [143]). 
To date, no one microRNA for the treatment of any cardiac disease has undergone 
human clinical investigation. Furthermore, the only microRNA suggested for the 
treatment of heart failure, miR-208, is still blocked at a preclinical stage, more than 6 
years after the first evidences of its effectiveness in small animal models [144].  A 
detailed description of the most relevant microRNAs in the context of cardiac 
hypertrophy is reported in the following sections. 
 
1.7.3.1 Anti-hypertrophic microRNAs  
1.7.3.1.1 The bicistronic cluster of miR-1 and  miR-133 
The miR-1-1 and miR-1-2 are among the most abundantly expressed microRNAs in the 
human heart and play an important role in CM morphology and function [131]. In terms 
of sequence, miR-1-1 and miR-1-2 are identical [145]. Twinfilin1 (Twf1), a cytoskeletal 
regulatory protein that binds actin monomers, preventing their assembly into filaments, 
was reported to be up-regulated by hypertrophic stimuli as aortic banding and alpha-
adrenergic stimulation by phenylephrine (PE) [134]. Li Q. and co-workers reported that 
twinfilin1 is down-regulated in the adult heart by miR-1, suggesting that the increased 
levels of this protein during hypertrophy is a consequence of the down-regulation of 
miR-1  [134].  miR-1 also negatively regulates the expression of the key calcium-
signalling components calmodulin (CaM); in a consistent manner, reduction of miR-1 
expression  correlates with activation of the Calcineurin-NFAT pathway [146]. 
Calcineurin is also negatively regulated by miR-133, the other member of the bicistronic 
cluster miR-133/miR-1 [147]. The miR-133 also targets NFATc4, one of the four 
calcineurin-activated NFAT family members, the overexpression of which is sufficient to 
promote cardiac hypertrophy in vivo [55]. In different rodent models of cardiac 
hypertrophy, both physiological and pathological, miR-1 and miR-133 are down-
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regulated [135], similar to what observed in patients with mitral stenosis and dilated 
atria [135]. On the other hand, overexpression of miR-133 in Akt Tg mice significant 
decreases both size of left ventricular CMs and expression of foetal genes, except for α-
skeletal actin [135]. Interestingly, the down-regulation of miR-133a can be detected 
only 8 week after aortic banding, whereas no change occurs at an earlier stage of 
hypertrophy (2 weeks), suggesting an involvement of miR-133a in late, maladaptive 
hypertrophic growth of the heart [148]. 
1.7.3.1.3 miR-9 
NFATc3 is another calcineurin-activated NFAT family members, regulating the 
expression of myocardin, a transcriptional co-activator that promotes cardiac 
hypertrophic responses [149] [150]. miR-9 was demonstrated to be a negative regulator 
of cardiac hypertrophy targeting NFATc3  [150] and, consistently, administration of a 
miR-9 mimic in models of isoproterenol-induced hypertrophy led to inhibition of 
hypertrophy and  decreased myocardin level [150]. 
1.7.4.1 Pro-hypertrophic microRNAs 
1.7.4.1.1 miR-195, a member of the miR-15 family 
MicroRNA-195 is a member of the miR-15 family that was shown to be up-regulated in 
cardiac tissue from both mice in response to TAC or expression of activated calcineurin 
[136]. Moreover, the over-expression of miR-195 in neonatal primary rat CMs evoked 
hypertrophic growth as well as cardiac overexpression of miR-195 in vivo was sufficient 
to drive cardiac hypertrophy, which rapidly transitioned to heart failure [136]. 
Interestingly, the miR-15 family (miR-15a, miR-15b, miR-16-1, miR-16-2, miR-195 and 
miR-497) was reported by Porrello et al. to be up-regulated in mouse hearts between 7 
and 14 days of age. In particular, mir-195 targets the expression of Check1 a cell cycle 
check-point gene that is implicated in the regulation of mitosis, coordinates 
progression through the G2/M and spindle checkpoints and regulates chromosome 
segregation and cytokinesis [151]. Taken together, this evidence  suggests a role of pro-
hypertrophic miR-195 in regulating the switch  between proliferation and hypertrophy, 
which is the predominant form of heart postnatal growth, which occurs immediately 
after birth. 
1.7.4.1.2 miR-199b 
The miR-199b was described as a direct downstream target of calcineurin/NFAT 
signalling [137]. miR-199b targets the dual specificity tyrosine-phosphorylation-
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regulated kinase 1a (Dyrk1a), an NFAT kinase [137]. Accordingly, decreased levels of 
Dyrk1a were found in patients with HF together with increased levels of miR-199b [137]. 
Moreover, mice treated with a miR-199b antagomir subjected to pressure overload 
showed normalized levels of Dyrk1A expression, no activation of the foetal gene 
program, attenuated levels of interstitial fibrosis and reduced CM size [137]. 
1.7.4.1.3 miR-23a 
MircroRNA-23a was found to be the most induced microRNA in the rat heart after two 
weeks of pressure overload [152]. miR-23a is a member of the microRNA-23a~27a~24-2 
cluster and was found  up-regulated in neonatal rat CMs upon treatment with either 
isoproterenol or aldosterone [140]. The expression of miR-23a is regulated by NFATc3, 
which directly binds the promoter region of the microRNA-23a~27a~24-2 cluster gene 
locus. In fact, cyclosporine A, an inhibitor of calcineurin, blunts both isoproterenol-
induced myocyte growth and miR-23a expression [140]. Luciferase activity assay 
identified the muscle-specific ring finger protein1 (Murf1) as a down-stream target of 
miR-23a, and overexpression of Murf1 in CMs was able to inhibit the hypertrophic 
response elicited by miR-23a [140]. 
1.7.3.1.4 miR-212 /132 
The miR212/132 family is an evolutionary conserved family of microRNAs, which are 
known to promote cardiac hypertrophy both in vitro and in vivo [138]. In particular, 
miR-212/132 family promotes CMs hypertrophic growth via direct downregulation of 
FoxO3 expression [138]. FoxO3 exerts its anti-hypertrophic effect mainly activating 
atrogin-1, which induces the ubiquitination and consequent degradation of 
Calcineurin-A [138]. Therefore, increased calcineurin phosphatase activity and increased 
NFAT activity were detected in the heart of transgenic mice over-expressing miR-
212/132 (miR-212/132-Tg) under the control of αMHC promoter [138]. Moreover, the 
analysis of cardiac functional parameters in miR-212/132-Tg mice depicted a severe 
status of pathological cardiac hypertrophy resulting in HF development [138]. On the 
other hand, miR-212/132 -/- mice were protected from TAC-induced hypertrophy as 
well as wt mice, submitted to TAC surgery and injected intravenously with antagomirs 
targeting both miR-212 and miR-132 [138].  
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1.8 Adeno-Associated Viral Vectors (AAVs)  
The Adeno-associated viruses (AAV) are small, with a diameter of 18-25 nm. They are 
single stranded (ss) DNA virus, and are non-enveloped. AAV belong to the family 
Parvoviridae and the genus Dependovirus. The main feature that differentiates AAV 
from the other genus (erythroviruses) of the Parvoviridae family is the inability of 
autonomous replication. In particular, the infectivity of AAV depends on the super-
infection with another virus [153]. The first factor identified as a successful helper in the 
generation of AAV particles was Adenovirus, hence the name Adeno-associated [153]. 
Moreover, wt AAV2 can integrate into chromosome 19q13.4 [154]. Hundreds of 
naturally occurring AAV serotypes have been identified to date and each serotype has a 
specific tropism for different tissues, mainly determined by its ability to bind specific cell 
surface primary receptors.  
1.8.1 Genome organization  
AAVs have a linear ssDNA genome with a length of approximately 4.7 kb. The AAV 
genome contains two long inverted terminal repeats (ITRs) flanking two open reading 
frames, corresponding to the genes rep and cap [155]. An additional gene, AAP, is 
nested within the cap gene and codes for a recently discovered protein assisting virion 
assembly [156] (Figure 5 panel A). The rep region encodes for replication-related 
proteins while the cap region encodes for the three structural proteins VP1, VP2, and 
VP3 that together form the viral capsid [155]. Two different promoters, p5 and p19, 
drive expression of the viral rep gene, resulting in the expression of four protein 
isoforms, namely Rep78, 68, 52 and 40. All four of these Rep proteins have helicase and 
ATPase activity but only Rep78 and Rep 68 have strand- and site-specific endonuclease 
and site-specific DNA binding activities.  
In particular, Rep78 and Rep68 bind specific sites within the ITRs, and are required for 
both viral DNA replication and site-specific integration whilst Rep52 and Rep40 are 
involved in the generation of single-stranded viral genomes for packaging into AAV 
capsids [155]. On the other hand, transcripts encoding for VP1, VP2 and VP3 are 
transcribed from the cap gene from the p40 promoter, but using three different start 
sites for translation. Sixty units of VP1, VP2 and VP3 assemble together with the ratio of 
1:1:18, thus generating a capsid shell with icosahedral symmetry and a diameter of 18-
25 nm [157]. Each viral particle contains the viral genome: a single stranded DNA 
molecule having either positive or negative polarity [157]. The VP1 protein also contains 
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a phospholipase A2 (PLA2) motif, fundamental for AAV escape from the endosomes 
[158]. 
The coding region of the viral genome is flanked at both ends by two identical long 
inverted terminal repeats (ITRs). The ITRs are of 125 nt containing a palindromic 
sequence, which forms a T-shaped hairpin structure [159]. The ITRs, due to their 
structure, provide a free 3’ hydroxyl group that is essential for the initiation of viral DNA 
replication by the cellular polymerase in a primase independent manner [160] [154]. 
Due to their importance in AAV biology, the ITRs are the only sequences maintained 
during the generation of recombinant AAV vectors (Figure 5 panel B). 
1.8.2 AAV infection 
1.8.2.1 Docking to the cell membrane  
During the early phases of AAV infection, the virus binds to specific receptors, which 
mediate its internalization. In particular, AAV interacts with primary receptors, which 
differ across serotypes, but after virus binding the interaction with a secondary receptor 
is necessary for the internalization of the virus. Heparan sulfate proteoglycan (HSPG) is 
the primary receptor for AAV2, AAV3 [161]; sialic acid for AAV1, AAV4, AAV5, AAV6; the 
37/67 kDa laminin receptor for AAV8; and N-linked glycans with terminal galactosyl 
residues for AAV9. Up to now, five co-receptors are known for AAV2 including α vβ5 
integrins [162], fibroblast growth factor receptor 1 FGFR1 [163], hepatocyte growth 
factor (c-Met) [164], αvβ1 integrin [165], 37/67 kDa laminin receptor  [166].  
1.8.2.2 Endocytosis and cytoplasmatic trafficking 
The next phase in AAV viral entry is internalization and it can involve different pathways 
of endocytosis; however, the events that characterize AAV-entry and post-entry 
trafficking are still not completely described. To successfully infect cells, AAV viral 
particles need to escape from the endocytosis pathway, thus avoiding degradation. 
Escape from endosomes is mainly due to the activity of the viral phospholipase A2 
(vPLA2) motif (HDXXY), which is present at the N-terminal of VP1; accordingly, 
mutations into this domain impair AAV infectivity [158]. Due to the lowering of 
endosomal pH during vesicle maturation, VP1 undergoes a conformational change that 
mediates the exposure of the N-terminal ends of VP1, which contains the vPLA2 domain 
as well as nuclear localization signals (NLS) [158, 167]. The PLA2 domain was reported to 
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induce pore formation in the endocytic vesicles, thus allowing the virus to escape and, 
thanks to the exposed NLS, to translocate into the nucleus [168] [167]. 
1.8.2.3 Nuclear entry and viral uncoating 
 Little is still known on the processes that control the nuclear translocation of the virus 
across the nuclear membrane. Previous reports suggested a passive diffusion model 
across nuclear pores [169] as well as a pore-independent mechanism of AAV nuclear 
entry [170]. However, it was recently shown that nuclear entry of rAAV2 is mainly 
dependent on the canonical nuclear import pathway, involving an active importin-β 
mechanism [167]. A study by Sessiseberger et al. reports the presence of GFP-labeled 
AAV viral capsids into the nucleus, thus suggesting that viral uncoating occurs after 
nuclear entry [171]. On the other hand, Lux et al. originally showed that viral uncoating 
occurs before and during nuclear entry [172]. A more recent study, however, has 
demonstrated that AAV2 virions enters the nucleus and accumulate in the nucleolus 
[173], thus confirming that viral uncoating occurs into the nucleus. In accordance, the 
nuclear injection of antibody against intact capsids considerably reduces AAV-infectivity 
[174]. 
 
1.8.2.4 Genome processing 
To be transcribed, AAV genomes have to be converted from ssDNA to dsDNA. The 
mechanism by which this conversion occurs is still debated; nevertheless it is generally 
accepted that: 1) a cellular polymerase is needed for second-strand synthesis [154]; 2) 
DNA damaging agents (for example, ultraviolet- or γ -radiation) as well as agents that 
blocs DNA synthesis (for example, hydroxyurea or topoisomerase inhibitors) increase 
rAAV2 transduction in vitro [175]; 3) self-annealing of complementary AAV (+) and (-) 
single-stranded genomes contributes to the generation of double-stranded AAV 
genomes [176]. 
1.8.3 Recombinant AAV 
The first attempts to use AAV as a tool for the expression of exogenous genes in 
mammalian cells took place in the 1980s, thus funding the basis of recombinant-AAV 
(rAAV) biology [177]. In rAAV vectors, the rep and cap genes are removed and the 
expression cassette is cloned in between of the two145 bp ITRs, which are the only 
sequences of the WT virus required as cis-elements for successful expression of the 
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cDNA (Figure 5 panel B). Any kind of promoter is suitable for the expression of the 
insert, whose size is restricted to a maximum of 4 - 4.5 kb. In the absence of the rep 
gene, rAAV vectors persist inside the cells mainly as extra-chromosomal DNA, thus 
allowing a long-term expression in non-dividing cells [178].  Since AAV2 is still the best-
characterized AAV serotype, its genome has been combined with different capsid 
serotypes in order to generate the most suitable rAAV vector for each tissue. Up to date, 
the most exploited strategy for the production of rAAV preparation in a helper-free 
method is based on the transfection of HEK293cells with three plasmids: 1) an AAV2-
ITR-containing plasmid carrying the gene of interest; (2) a plasmid carrying the Rep-Cap 
for the desired serotype; (3) a plasmid expressing the helper genes (E4, VA, E2A) from 
adenovirus (Figure 5 panel C). In particular, rAAV vectors have been shown to be very 
efficient in transducing post-mitotic tissues such as brain (neurons; rAAV9), heart (CMs; 
rAAV9 [179], rAAV6 [180]), retina (photoreceptors; rAAV5, rAAV8 [181]) skeletal muscle 
(myofibers; rAAV1, rAAV6 and rAAV7 [182] [183]), liver (hepatocytes; rAAV8 and rAAV9 
[184]) and pancreas (endocrine/exocrine pancreas; rAAV8, rAAV6 [185]). 
 
1.8.4. Clinical applications of gene transfer using rAAV 
The two most used vectors for the treatment of genetic disorders using gene therapy 
are lentiviruses, for ex vivo gene transfer into haematopoietic and other stem cells, and 
rAAV for in vivo gene transfer into post mitotic tissues for which the vector has tropism. 
Both viral based- approaches present different drawbacks: on the one hand, lentiviruses 
raise a major safety issue related to insertional mutagenesis, while, on the other hand, 
pre-existing or acquired neutralizing antibody activity against AAV capsid is a major 
limitation for efficient in vivo gene transfer using AAV vectors. 
According to the Wiley Gene Therapy database updated on April 2017 
(http://www.abedia.com/wiley/), 183 clinical trials have been conducted so far using 
rAAV vectors.  Of these studies, it is worth mentioning the successful gene transfer to 
the subretinal space of the retinal pigment epithelium-specific 65 kDa protein (RPE65) 
in patients with Leber Congenital Amaurosis (LCA) caused by mutations in the RPE65 
gene, which is currently in Phase III (NCT00999609). Due to the immune-privileged 
injection site, the immune response against the vector and the transgene were minimal 
in this trial, thus providing the groundwork for trials for a host of more common 
inherited retinal degenerative disorders, such as Leber’s hereditary optic neuropathy 
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(ClinicalTrials.gov identifier: NCT02161380), choroideraemia (ClinicalTrials.gov identifier: 
NCT02553135; NCT02341807; NCT02407678), X-linked retinoschisis (ClinicalTrials.gov 
identifier: NCT00055029) and age-related macular degeneration (ClinicalTrials.gov 
identifier:  NCT01024998).  
Another attractive tissue for gene transfer is the skeletal muscle, which can be targeted 
with treatments aimed not only at correcting neuromuscular diseases but also exploited 
for the production of recombinant proteins that are missing in inherited protein 
deficiencies such as haemophilia, α1-antitrypsin deficiency and lipoprotein lipase (LPL) 
deficiency.  The most widely used administration route to the skeletal muscle is direct 
intramuscular injection and the most efficient AAV serotypes for muscle transduction 
are AAV1 and AAV2 (reviewed in [186]). This delivery route is procedurally simple, the 
vector dissemination to other organs is minimal and pre-existing anti-capsid antibody 
does not block transduction [187]. Conversely, the skeletal muscle has been shown to 
be an organ that develops strong anti-transgene immune response [188]. In addition, in 
disease such as Duchenne muscular dystrophy, the transduction of most muscle 
groups, such as the diaphragm for which a clinically available procedure is not yet 
established, represents an important limit to the therapeutic efficacy of this approach. 
Interestingly, the first gene therapy approved in the Western world is Glybera (alipogen 
tiparvovec, AAV1-LPL), which consists of an AAV1 encoding for the human LPL. The 
therapy consists of LPL, encoded by an AAV1 virus vector, administered in a one-time 
series of up to 60 intramuscular injections in combination with immunosuppressive 
regimen is recommended from three days prior to and for 12 weeks following Glybera 
administration [189]. Recently, however, Glybera was withdrawn from the market 
mainly due to marketing considerations, especially related to its disproportionately high 
price (over 1 million Euro per patient) compared to the prevalence of the disease. 
So far all clinical trials conducted for the gene transfer to the cardiac tissues were aimed 
at the over-expression of the sarco/endoplasmic reticulum Ca2+-ATPase (Serca2a) in 
patients with chronic heart failure.  In particular, the Serca2a upregulation by intra-
coronary administration using an adeno-associated virus type 1/sarcoplasmic reticulum 
Ca(2+)-ATPase in patients with heart failure (CUPID ClinicalTrials.gov identifier: 
NCT00454818) demonstrated safety and suggested benefit of the treatment, 
supporting larger confirmatory trials [190]. Following this was the CUPID2 trial 
(ClinicalTrials.gov identifier: NCT01643330)[191], a placebo-controlled phase 2b trial 
with 250 enrolled patients, which despite earlier promise in the CUPID trial failed to 
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reach the primary end point. A composite of HF hospitalization or ambulatory 
treatment for worsening heart failure at 12 months was 0.93 (95% CI 0.53-1.65, P=0.81) 
[192]. Unfortunately, a Phase III follow up clinical trial (AGENT-HF) has not confirmed this 
preliminary positive outcome [191]. 
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Materials and methods 
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All the laboratory reagents used in this research project were purchased from standard 
suppliers. All the solutions and buffers were prepared with MilliQ (Millipore) quality 
water and, depending to the protocol, solutions were sterile filtered (0.22μm pores) 
before use. Table 1 reports a detailed description of all the reagents used. 
2.1 Cellular biology protocols 
2.1.1 Cell line culture 
2.1.1.1 HeLa cells 
HeLa cells were incubated in D-MEM 1gr/l glucose medium with 10% fetal bovine 
serum and penicillin/streptomycin 100 U/mL. Cells were passaged every 3 days. 
2.1.2 Isolation and culture of primary neonatal rat/mouse ventricular 
cardiomyocytes 
Wistar rats were purchased from Charles River Laboratories Italia Srl. Animal care and 
treatments were conducted in conformity with institutional guidelines in compliance 
with national and international laws and policies (EEC Council Directive 86/609, OJL 358, 
December 12, 1987). 
Ventricular CMs from neonatal rats/mice have been separated from the atria, cut into 
smaller pieces and then digested, at room temperature using CBFHH buffer (calcium 
and bicarbonate-free Hanks with HEPES) supplemented with 1.75mg/ml trypsin (BD 
Difco) and 10 μ g/ml DNaseI (SIGMA). The collected supernatant was centrifuged to 
separate the cells, which were then re-suspended in DMEM, high glucose 
supplemented with vitamin B12 (Sigma), 5% of foetal bovine serum (FBS, Life 
Technologies) and with 100U/ml of penicillin and 100 μg/ml of streptomycin (Pen-Strep, 
Sigma). The collected cells were strained in a cell strainer (40μm, BD Falcon) and then 
seeded on uncoated 100 mm dishes (DB Falcon) for 2 hours at 37°C in 5% C02. The 
cardiomycytes are now mainly in the supernatant, which was then collected, counted 
and plated at the desired density in primary or collagen coated plates. 
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2.1.3 Transfection protocols 
2.1.3.1 Transfection of rat CMs with human microRNAs: 
The microRNAs mimics were transfected into neonatal rat CMs using a standard or 
reverse transfection protocol, at a final microRNA concentration of 25  nM.  
− Reverse transfection: 7.5 μ l of each microRNA 500nM concentrated were 
spotted into each well (final reaction volume 150 μl). The transfection reagent 
(Lipofectamine RNAiMAX, Life Technologies) was diluted in OPTI-MEM (Life 
Technologies) and incubated for 5 minutes (final volume was calculated 
considering 0.2 μl of RNAiMAX and 25 μl of OPTI-MEM for each well). The mixture 
of transfection reagent and OPTI-MEM was added to the microRNAs previously 
spotted into each well and incubated for 30 minutes. Immediately after 
1.0  ×  104 cells/well were seeded. Here below it follows a detailed description of 
the transfection procedure optimized for different well format: 
• MicroRNA transfection protocol 96 well plates format, mix per 
well: 
- 7.5 μl of microRNA 500nM 
- 25 μl of OPTI-MEM 
- 0,2 μl of RNAiMAX 
• Procedure : 
1. Incubate RNAiMAX and Opti-MEM medium (Gibco) for 5 minutes at RT  
2. Dispense 25μl/well of transfection MIX on plates spotted with the 
microRNA; incubate for 30 minutes at RT  
3. Dispense 1.0  ×  10^4 rat CMs (118μl total volume) into each well  
4. Change medium 24 hours after transfection 
5. Incubate for 48 hours  
6. Wash the cells 3 times in PBS (100μl/well), fixed in 4% PFA (50μl/well) 
 
− Forward transfection: The transfection reagent (Lipofectamine RNAiMAX, Life 
Technologies) was diluted in OPTI-MEM (Life Technologies) and incubated for 5 
minutes (final volume was calculated considering 0.2 μl of RNAiMAX and 25ul of 
OPTI-MEM for each well).  25 μl of transfection mixture were added to 1.5ml 
Eppendorf Tubes containing 7.5 μl of each microRNA (500 nM concentrated) and  
incubated for 30 minutes. Immediately after 32.5 μ l of mixture was transferred 
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into each well, where 1.0  ×  104 cells had been seeded 24 hours before (final 
volume 150μl /well). 
• MicroRNA Transfection protocol 96 well plates format, mix per 
well: 
− 7.5 μl of microRNA 500nM 
− 25 μl of OPTI-MEM 
− 0,2 μl of RNAiMAX 
• Procedure : 
1. Incubate RNAiMAX and Opti-MEM medium (Gibco) for 5 minutes at RT  
2. Dispense 25μl/well of transfection MIX into 1.5ml eppendorf tube 
containing the 7.5 μ l /well of microRNA (500nM); incubate for 30 
minutes at RT  
3. Dispense 32.5 μl of mix/well on top of previously seeded rat CMs 
1.0  ×  10^4 cells/well (150 μl final volume). 
4. Change medium  24 hours after transfection 
5. Incubate for 48 hours  
6. Wash the cells 3 times in PBS (100μl/well) 
7. Fix the cells in 4% PFA (50μl/well) 
 
2.1.3.2 Forward Transfection of rat cardiomyocytes with human microRNAs in 
35mm dishes 
The transfection reagent (Lipofectamine RNAiMAX, Life Technologies) was diluted in 
OPTI-MEM (Life Technologies) and incubated for 5 minutes (final volume was calculated 
considering 4 μ l of RNAiMAX and 500 μ l of OPTI-MEM for each dish).  500 μ l  of 
transfection mixture were added to 1.5ml Eppendorf Tubes containing 15 μ l of each 
microRNA (5μM concentrated) and  incubated for 30 minutes. Immediately after 515 μl 
of mixture was transferred into each well, where 2   ×  106 cells were seeded 24 hours 
before (final volume 3ml /dish). 
• MicroRNA Transfection protocol 35mm dish format, mix per well: 
− 15 μl of microRNA 5uM 
− 500 μl of optimum 
− 4 μl of RNAiMAX 
• Procedure: 
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1. Incubate RNAiMAX and Opti-MEM medium (Gibco) for 5 minutes at RT  
2. Dispense 500μl/well of transfection MIX into 1.5ml eppendorf tube 
containing the 7.5 μl /well of microRNA (500nM); incubate for 30 minutes 
at RT  
3. Dispense 500 μ l of mix/well on top of previously seeded rat CMs 
2.0  ×  10^6 cells/well (2.5 ml final volume). 
4. Incubate cells for 72 hours. 
2.1.3.3 Transfection of mouse cardiomyocytes with human microRNAs 
Human microRNAs transfection in mouse CMs follows the same protocol for rat CMs 
described in section 2.1.3.1 and 2.1.3.2. The only difference is the final concentration of 
microRNAs that was optimized at 50 nM for mouse CMs  instead of 25 nM for rat CMs. 
2.1.3.4 pDNA and microRNA transfection in HeLa cells 
2.1.3.4.1 MicroRNA transfection 
HeLa (human cervical cancer) cells were transfected with MC1 or hsa-miR-665 at a final 
concentration of 50 nM in 96-well plates, through a standard reverse transfection 
protocol similar to that described in section 2.1.3.1. 
2.1.3.4.2 Plasmidic DNA transfection 
HeLa cells were transfected with 100 ng per well (96 well plate) of pDNA using FuGENE 
HD as transfection reagent (Promega). The optimized ratio of pDNA:lipids is 1:3. 
• pDNA Transfection protocol 96 well plate format, mix per well: 
− 100 ng of pDNA 
− 30 μl of OPTI-MEM 
− 0.3 μl of FugeneHD 
• Procedure: 
1. Dilute pDNA into OPTI-MEM 
2. Prepare the transfection mix adding 0.3 μ l of Fugene HD each 100 ng of 
pDNA, vortex and incubate for 20 minutes at RT  
3. Dispense 20 μ l of transfection mix/well on top of 1.2  ×  104 HeLa cells 
seeded 24 hours before. 
4. Incubate cells for 72 hours. 
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2.1.4 Human microRNA screening in rat cardiomyocytes 
The microRNA mimics (miRDIAN microRNA mimics; Dharmacon) library corresponding 
to the all human mature microRNAs (988 microRNAs, 875 unique sequences miRBase 
release 13.0 (2009), http://mirbase.org;) were obtained by Dharmacon, Fhisher Thermo 
Scientific. The library of microRNAs was robotically (Hamilton StarLab) replicated from 
stock library plates to Primaria 96-well plates (BD Falcon); 7.5 μl  of each microRNA 
500nM concentrated were spotted into each well leaving columns 1 and 12 empty for 
addition of controls (buffer, MC1, MC4). MicroRNAs were transfected into neonatal rat 
CMs using a standard reverse transfection protocol, at a final microRNA concentration 
of 25  nM (final volume 150 μl). Briefly, the transfection reagent (Lipofectamine 
RNAiMAX, Life Technologies) was diluted in OPTI-MEM (Life Technologies) and 
incubated for 5 minutes (final volume was calculated considering 0.2 μ l of RNAiMAX 
and 25 μ l of OPTI-MEM for each well). The mixture of transfection reagent and OPTI-
MEM was robotically added to the microRNAs arrayed on 96-well plates, using the 
Multidrop™ reagent dispenser (Thermo Fisher SCIENTIFIC). Transfection mix and 
microRNA were incubated for 30 minutes and immediately after 1.0  ×  104 cells/well 
were robotically seeded using the Multidrop™ reagent dispenser (Thermo Fisher 
SCIENTIFIC). Twenty-four hours after transfection, culture medium was replaced by fresh 
medium; 28  h later, that is, 52  h after plating, the culture medium was replaced with 
medium containing 5  µM 5-ethynyl-2′-deoxyuridine (EdU, Life Technologies) for 20  h. 
Cells were fixed at 72  h after plating using 4% PFA and processed for 
immunofluorescence. The screenings were performed at the ICGEB High-Throughput 
Screening Facility (http://www.icgeb.org/high-throughput-screening.html). 
 
2.1.5 Mouse  siRNAs screening in mouse cardiomyocytes 
For the transfection experiments in mouse CMs, the selected siRNAs (list reported in 
Table 3) were “cherry-picked” from siRNA library stock plates and robotically re-arrayed 
into collagen-coated black clear-bottom 384-well plates (PerkinElmer) using the Starlab 
Liquid handler (Hamilton). Transfection was performed as described in section 2.1.3.3, in 
particular 7.5  ×  104 cells were seeded per well and a final microRNA concentration of 
50  nM was used. The screenings were performed at the ICGEB High-Throughput 
Screening Facility (http://www.icgeb.org/high-throughput-screening.html). 
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2.2 Molecular biology protocols 
2.2.1 UTR-luciferase reporter: construct generation 
Portions of the 3’-UTR of Enah, Fhl1 and the 5’-UTR of XIrp2 were obtained by gene 
synthesis (gBlocks) from IDT (Integrated DNA Technology) and sub-cloned into 
psiCHECK2 vector (Promega). The extremities of gBlocks were implemented with 
restriction sites for XhoI and NotI in addition to flanking regions of stuffer-DNA to 
increase cut efficiency.  
The gBlocks were then digested with XhoI  (New England Biolabs) and Not-HF (New 
England Biolabs) according to the following protocol: 
• GBlocks digestion protocol: 
− Prepare the following digestion mix and incubate at 37° for 2 hours 
I. 500 ng of gBlock 
II. 0.1μl of XhoI (10000U/ml) 
III. 0.1μl of NotI-HF (10000U/ml) 
IV. 2μl  of 10x Buffer 2.1 (New England Biolabs) 
V. H20 to final volume of 20 μl 
The psiCHECK2 vector was linearized with XhoI  (New England Biolabs) and Not-HF 
(New England Biolabs) according to the following protocol: 
• PsiCHECK2-Vector preparation: 
− Prepare the following digestion mix and incubate at 37° for 2 hours 
I. 2 μg of the vector 
II. 0.5μl of XhoI (10000U/ml) 
III. 0.5μl of NotI-HF (10000U/ml) 
IV. 3μl of 10x Buffer 2.1 (New England Biolabs 
V. H20 to final volume of 30 μl 
− The digestion reaction was heat inactivated (15’ at 65°C) and submitted 
to DNA gel electrophoresis. 1% agarose gel was prepared place into an 
electrophoresis chamber and rinsed in TBE (Tris-Borate-EDTA buffer; 
SIGMA). The samples were loaded into pre-cast wells and when placed in 
an electric field, due to the negatively uniform mass/charge ratio of 
nucleic acids, DNA fragments migrate according to their molecular 
weight and secondary structure. The linearized vector was then excised 
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and purified by gel using Wizard SV Gel and PCR Clean-Up System 
(Promega) according to manufacture’s instruction. 
Linearized vector and digested gBlocks were ligated and transformed into into XL10 
Gold (Stratagene) recombination deficient bacteria. Colonies were screened for 
ampicillin resistance as well as insert size by restriction enzyme digestion. 
• Cloning of gBlocks into PsiCHECK2-Vector: 
The vector ligated with the inserts with the following reaction 60’ at room 
temperature: 
I. 50ng of purified vector 
II. 50ng of gBlocks 
III. 1 μl of the DNA ligase T4 (New England Biolabs) 
IV. 2 μl of DNA ligase T4 10x Buffer (New England Biolabs) 
V. H20 to final volume of 20 μl 
− The ligation reaction was heat inactivated (15 minutes at 65°C) and 
transformed into XL10 Gold (Stratagene) recombination deficient 
bacteria by heat shock, following manufacture’s instruction. The cells 
were then plated on Ampicillin selective agar. 
− Single colonies were picked and plasmidic DNA purification performed 
using the Wizard SV MiniPrep system (Promega) according to 
manufacture’s instruction. 
− The so obtained DNA was digested with XhoI and NotI restriction 
enzymes following the aforementioned protocol; only positive clones 
show right size insert excision. 
− The digestion reaction was heat inactivated (15’ at 65°C) and submitted 
to DNA gel electrophoresis. 2 % agarose gel was prepared place into an 
electrophoresis chamber and rinsed in TBE (Tris-Borate-EDTA buffer; 
SIGMA). The samples were loaded into pre-cast wells and when placed in 
an electric field, due to the negatively uniform mass/charge ratio of 
nucleic acids, DNA fragments migrate according to their molecular 
weight and secondary structure. 100bp and 1kb ladder (New England 
Bioloabs) were used.  
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2.2.2 UTR-luciferase reporter: Assay 
HeLa cells were reverse transfected with MC1, hsa-miR-665 at a final concentration of 50 
nM in 96-well plates. Twenty-four hours after microRNAs transfection, cells were 
transfected with 100 ng per well of the reporter constructs or psiCHECK2 vector 
(control) using FuGENE HD transfection reagent (Promega) (transfection protocols 
described section 2.1.3.4). Firefly and Renilla luciferase activities were measured 
(Envision plate reader (PerkinElmer), 1second integration signal), 36 hours after plasmid 
transfection using Dual-Glo® Luciferase Assay System, according to the manufacturer’s 
instructions. 
2.2.3 Total RNA isolation from total heart and cultured cardiomyocytes 
In the case of RNA extraction from whole hearts, hearts were removed by gross 
dissection from the body, washed in PBS and snap frozen in liquid nitrogen. Once 
frozen the samples were stored at -80°C for further processing. The same day of RNA 
extraction 1 ml of TRIzol reagent (Invitrogen, Carlsbad, CA, USA) was added to each 
heart samples and efficiently disrupted using the MagNA Lyser Instrument (ROCHE). In 
the case of cultured rat or mouse CMs, cells were washed in PBS and directly lysed using 
TRIzol reagent (1ml for ≅250 thousands CMs) (Invitrogen, Carlsbad, CA, USA). After 
either tissue homogenization or cell lysis supernatant containing nucleic acids were 
recovered and submitted to RNA extraction using the miRneasy mini kit (Quiagen), 
according to the manufacturer’s instructions. 
2.2.4 Quantitation of nucleic acids by real-time PCR 
Total RNA from isolated CMs was reverse-transcribed using hexameric random primers 
(Invitrogen), starting from 250 ng of RNA. The cDNA was used as a template for real-
time PCR amplification to detect the expression levels of selected genes. The 
housekeeping gene GAPDH was used to normalize the results. Quantification of gene 
expression was performed by quantitative real-time PCR, using TaqMan® assays 
(Applied Biosystems) reported in Table 2. 
TaqMan assays employ a sequence-specific, fluorescently labelled oligonucleotide 
probe called the TaqMan probe, in addition to the sequence-specific primers. Also 
known as the 5'-nuclease assay, the TaqMan assay exploits the 5'-exonuclease activity of 
thermophilus aquaticus polymerase (Taq). The probe contains a fluorescent reporter at 
the 5' end and a quencher at the 3' end. When intact, the fluorescence of the reporter is 
 49 
quenched due to its proximity to the quencher. During the combined 
annealing/extension step of the amplification reaction, the probe hybridizes to the 
target and the dsDNA-specific 5' to 3' exonuclease activity of Taq cleaves off the 
reporter. As a result, the reporter is separated from the quencher, and the resulting 
fluorescence signal is proportional to the amount of amplified product in the sample. 
One commonly used fluorescent reporter- quencher pair is fluorescein (FAM, which 
emits green fluorescence) and Black Hole Quencher 1. The main advantages of using 
TaqMan probes include high specificity and a high signal-to-noise ratio. 
2.2.4.1 Assay settings 
The adopted settings reported here below have been tested to ensure a reaction 
efficiency of 2. 
• Each reaction was composed in 20 μl:  
i) 10μl 2X PCR Master Mix (Biorad);  
ii) 1μl 20X primers and probe fluorofore FAM 
iii) 1μl cDNA 
iv) H2O to final volume. 
• The adopted protocol was: 
i) 95° 5 minutes 
ii) 44 cycles: 
1. 95° 10 seconds 
2. 60° 30 seconds 
3. Read 
i) Melting curve 60° to 95°- 0,5° increments 
 
2.2.4.2 Normalization method: The 2–∆∆CT (Livak) Method  
The 2–∆∆CT method for relative gene expression analysis is widely used and easy to 
perform.  
1) First, normalize the CT of the target gene to that of the reference (ref) gene, for 
both the test sample and the calibrator sample: 
a) ∆CT(test) = CT(target, test) – CT(ref, test) 
b) ∆CT(calibrator) = CT(target, calibrator) – CT(ref, calibrator) 
2) Second, normalize the ∆CT of the test sample to the ∆CT of the calibrator: 
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a) ∆∆CT = ∆CT(test) – ∆CT(calibrator) 
3) Finally, calculate the expression ratio: 
a) 2–∆∆CT = Normalized expression ratio 
 
The result obtained is the fold increase (or decrease) of the target gene in the test 
sample relative to the calibrator sample and is normalized to the expression of a 
reference gene. Normalizing the expression of the target gene to that of the reference 
gene compensates for any difference in the amount of sample. 
2.2.5 mRNA sequencing  
Left ventricle of hearts extracted from 8 weeks old TAC-operated CD1 mice injected 
with AAV9-hsa-miR-665 (N°=3) and AAV9-Control (N°=3) or 8 weeks old sham operated 
mice (N°=3) were processed for total RNA extraction (see protocol described in section 
3.2.3). Deep-sequencing was performed by IGA Technology Services. Samples were 
processed using TruSeq RNA-seq sample prep kit from Illumina. Briefly, the poly-A 
containing mRNA molecules were purified using poly-T oligo-attached magnetic beads, 
fragmented into small pieces using divalent cations under elevated temperature, cDNA 
was synthesized by reverse transcription and standard blunt-ending plus added ‘A’ was 
performed. Then, Illumina TruSeq adapters with indexes were ligated to the ends of the 
cDNA fragments. After ligation and separation of non-ligated adapters, only the 
fragments captured by complementary adapter oligonucleotides, which are covalently 
bound to Illumina flow cells, were extended and brigde-amplified to create milions of 
clusters, each of which contains thousands copies of a single template molecule. The 
clusters were sequenced at ultra-highthroughput on the Illumina HiSeq2000, obtaining 
30–57 millions of single-reads per sample, 50 bp long.   
Raw data were subjected to quality control using FASTQC tool 
(http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc) and, in order to estimate gene 
expression levels, only QC passing reads were subsequently mapped to the Mus 
musculus reference genome (University of California at Santa Cruz, UCSC, mm10) by 
using the ultrafast universal RNA-seq aligner STAR [193] and the Mouse Genecode 
release M12 (GRCm38.p5) as gene annotation file. Mapped reads for all transcript 
variants of a gene were combined into a single value to perform differential gene 
expression analysis. 
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The Bioconductor packages DESeq2 version 1.12.4 [194] and EdgeR [195] version 3.6.2 
in the framework of R software version 3.3.1 were used to perform the differential gene 
expression analysis of mRNAseq data. Both packages are based on the negative 
binomial distribution (NB) to model the gene reads counts and shrinkage estimator to 
estimate the per-gene NB dispersion parameters. Specifically, we used rounded gene 
counts as input and we estimated the per-gene NB dispersion parameter using the 
function DESeq for DESEQ2 while for edgeR we used the function calcNormFactors with 
the default parameters for the estimation of the biological coefficient of variation (BCV). 
Estimated p-values for each gene was adjusted using the Benjamini-Hochberg method 
[196] and adjusted P<0.05 was selected as statistical threshold. Using the number of 
replicas and the BCV as starting data for rnapower function [197] we estimated as 
optimal non statistical thresholds: 10 normalized counts and 1 absolute Logarithmic 
base 2 fold change.  
 
2.2.6 Immunofluorescence on culture rat and mouse cardiomyocytes 
2.2.6.1 Immunofluorescence in 96/384 well plate 
Cells were fixed with 4% paraformaldehyde (PFA) for 15 min (40μl/20μl), permeabilized 
with 0.5% Triton X-100 in phosphate buffered saline (PBS) solution for 10 min 
(40μl/20μl), followed by 30 min blocking in 1% bovine serum albumin (BSA, Roche) 
(40μl/20μl). Cells were then stained overnight at 4°C with the following primary 
antibodies diluted in blocking solution (BSA 1% in PBS): mouse monoclonal antibody 
against sarcomeric α-actinin 1:400 (Abcam), mouse monoclonal antibody against atrial 
natriuretic peptide 1:400 (ANP) (Millipore). Cells were washed with PBS (100μl/60μl) and 
incubated for 2 hours, at room temperature, with the selected secondary antibody 
labelled with Alexa Fluor-488 (green) or Alexa Fluor-594 (red). Cell nuclei were further 
stained with Hoechst 33342 (Life Technologies) diluted 1:5000 in PBS (100μl/50μl). 
 
2.2.6.2 EdU Staining in 96/384 well plate 
When indicated, cells were further processed using the Click-IT EdU 594 Imaging kit to 
reveal EdU incorporation, according to the manufacturer’s instructions. Cell nuclei were 
further stained with Hoechst 33342 (Life Technologies) diluted 1:5000 in PBS 
(100μl/50μl). 
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2.2.7 Histology 
At the end of the studies, animals were sacrificed by injection of 10% KCl, to stop the 
heart at diastole. Heart and tibia were removed by gross dissection from the body. Heart 
weight and tibia length were taken after the hearts were washed in PBS and chambers 
and tibias were cleaned of cartilaginous tissue. The heart was fixed in 10% formalin at 
room temperature, embedded in paraffin and further processed for histology 
2.2.7.1 Masson’s trichrome stain 
Masson’s trichrome stain is a tri-color stain that produces red keratin and muscle fibers, 
blue collagen and bone, pink cytoplasm, and dark brown to black cell nuclei. This 
peculiar stain is achieved by the combination of four different stains: Weigert’s iron 
hematoxylin for nuclei, picric acid for erythrocytes, a mixture of acid dyes (acid fuchsin-
”ponceau de xylidine”) for cytoplasm and aniline blue for connective tissue. 
After fixation in formalin, hearts were embedded in paraffin and processed for slides 
preparation. Sections were deparaffinised (65°C for 12 hours), rehydrated (5’-100% 
EtOh; 5’-95% EtOh, 5’-75% EtOh, 5’-50% EtOh, H20) and processed using a commercially 
available kit for Masson’s trichrome stain (BioOptica), according to the manufacturer’s 
instructions. After the staining the slides were dehydrated (5’-50% EtOh; 5’-75% EtOh, 
5’-95% EtOh, 5’-100% EtOh, H20) and mounted in Eukitt mounting medium by Sigma. 
2.2.7.2 Periodic acid-Shiff (PAS) stain 
The Periodic acid-Shiff (PAS) stain specifically detects glycogen, glycoproteins, 
glycolipids and mucins in tissues. Periodic acid oxidises glycols to aldehydes. These 
aldehydes then react with the Schiff reagent and releases a pararosaniline adduct, 
which stains the glycol-containing cellular elements in purple. Slides were 
deparaffinised (65°C for 12 hours), rehydrated (5’-100% EtOh; 5’-95% EtOh, 5’-75% EtOh, 
5’-50% EtOh, H20) and processed using the PAS staining kit (SigmaAldrich) to detects 
fibres border, according to the manufacturer’s instructions. After the staining the slides 
were dehydrated (5’-50% EtOh; 5’-75% EtOh, 5’-95% EtOh, 5’-100% EtOh, H20) and 
mounted in Eukitt mounting medium by Sigma. 
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2.2.7.3 Immunofluorescence on heart section 
After excision, the heart was fixed in 10% formalin at room temperature, embedded in 
paraffin and further processed for immunofluorescence. Sections were deparaffinised 
(65°C for 12 hours), rehydrated (5’-100% EtOh; 5’-95% EtOh, 5’-75% EtOh, 5’-50% EtOh, 
H20) and then underwent antigen retrieval by boiling in sodium citrate solution for 30 
min. Slides were processed for sarcomeric α -actinin, wheat germ agglutinin 
(WGA)staining). 
 
2.3 In vivo experiment protocol 
CD1 mice were purchased from Charles River Laboratories Italia Srl. Animal care and 
treatments were conducted in conformity with institutional guidelines in compliance 
with national and international laws and policies (EEC Council Directive 86/609, OJL 358, 
December 12, 1987). 
2.3.1 Aortic Banding and simultaneous intra-cardiac injection of AAV 
vectors 
Aortic banding was produced in adult female CD1 mice (10 weeks old), by permanent 
Aortic Arch constriction as described previously by deAlmeida and colleagues [198]. Our 
technique contains slight modifications to allow simultaneous intra-cardiac AAV 
injection. Briefly, mice were anesthetized with an i.p. injection of ketamine and xylazine, 
endotracheally intubated and placed on a rodent ventilator. Body temperature was 
maintained at 37°C on a heating pad. The Aortic Arch and beating heart was accessed 
via superior median sternotomy prolonged until 4th intercostal space. A chest dilatator 
was used to optimize heart and vessels visualization. After gentle separation of the 
thymus fat tissue from the vessels of interest, constriction of Aortic Arch was performed 
against a 2 gauge needle with 7.0 silk suture knots. Immediately post-ligation, 
recombinant AAV vectors, at a dose of 1×1011 vg per animal, were injected in left 
ventricle anterior wall (single injection) about 1 mm under the left atrium, using an 
insulin syringe with incorporated 30-gauge needle. Two groups of animals were 
studied, receiving AAV9-control and AAV9-hsa-miR-665. The chest was closed, and the 
animals moved to a prone position until the occurrence of spontaneous breathing. 
Echocardiography analysis was performed at days 12, 30 and 60 days after banding, and 
hearts were collected at 30 (n=8 animals per group) and 60 (n=8 animals per group) 
days after banding. 
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2.3.2 Aortic Banding and subsequent intra-cardiac injection of AAV vectors 
This model was designed in order to assess whether has-miR-665 was able to revert an 
already established hypertrophic phenotype. For this purpose, aortic banding was 
produced (same procedure in 3.3.1) and immediately post ligation the chest was closed 
and the animals moved to a prone position until the occurrence of spontaneous 
breathing. All the animals underwent echocardiography 15 days after banding to assess 
the severity of the hypertrophic phenotype and then divided into two homogenous 
groups. Both control and treated groups underwent intra-cardiac injection (same 
procedure in 3.3.1) respectively with AAV9-control and AAV9-miR-665. 
Echocardiography analysis was performed at days 15, 30 and 60 days after AAV9 
injection, and hearts were collected at 30 (n=8 animals per group) and 60 (n=8 animals 
per group) days after banding. 
2.3.3 Echocardiography analysis 
To evaluate left ventricular function and dimensions, transthoracic two-dimensional 
echocardiography was performed on mice sedated with 5% isofluorane at 15, 30 and 60 
days after aortic banding, using a Visual Sonics Vevo 770 Ultrasound (Visual Sonics) 
equipped with a 30 MHz linear array transducer. M-mode tracings in parasternal short 
axis view were used to measure left ventricular anterior and posterior wall thickness and 
left ventricular internal diameter at end-systole and end-diastole, which were used to 
calculate left ventricular ejection fraction. 
2.4 Statistics 
The Prism package (GraphPad Software, La Jolla, CA) was used to analyse the data. All the 
results are expressed as mean ± s.d. Values of p<0.05 were considered statistically 
significant. Depending on the experimental design, Student’s t-test, one-way ANOVA or 
two-way ANOVA with Tukey’s post-hoc comparison tests were used, as indicated in the 
legends to the figures and text. Correlation analyses were done using the Pearson 
coefficient to assess the linearity between two variables and calculate two-tailed p-value 
(95% of confidence interval). 
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RESULTS 
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3.1 High-content, fluorescence-microscopy-based, high-throughput 
screen identifies microRNAs able to modify cardiomyocytes area 
A high-content, fluorescence-microscopy-based, high-throughput screen was 
performed in neonatal rat CMs using a library of 875 microRNA mimics (988 mature 
microRNAs, 875 unique sequences, miRBase release 13.0 (2009), http://mirbase.org). 
MicroRNA mimics were introduced into cultures of neonatal rat ventricular CMs by 
reverse transfection. To assess efficiency of the procedure, several wells were 
transfected with a toxic siRNA against the UBC component of the ubiquitin-proteasome 
pathway, followed by nuclear count. By this approach, efficiency of transfection was 
estimated ≥ 92% (Figure 6 panels B and C).  
After 72 h from reverse transfection, cells were stained for sarcomeric α -actinin to 
specifically measure CM cell size and number and for uptake of 5-ethynyl-29-
deoxyuridine (EdU), a uridine analogue that is incorporated into newly synthesized DNA 
(experimental scheme in Figure 6, panel A). Image segmentation and analysis was 
performed to selectively quantify CM size and number of proliferating CMs (Figure 6, 
panel G). Figure 6 panel E reports correlation between CM size and percentage of 
proliferating cells following treatment with the 875 microRNAs. The screening was 
performed in duplicate; the replicates showed very good reproducibility (Spearman 
coefficient 0.84; Fig. 6D). On average, approximately 2,500 cells were analysed per 
experimental condition and replicate. Representative images of microRNAs able to 
strongly reduce or increase CM cell size are shown in panel G, and include hsa-miR-665 
and hsa-miR-664-5p.  
Next we decided to individually study each of those microRNAs unable to promote EdU 
incorporation but able to influence CM cell size. According to these parameters, 11 
microRNAs were selected: 4 of these induced CM hypertrophy and 7 instead reduced 
cell size (Figure 6, panel F). 
 
3.2 Validation of the screening hits 
Based on the screening results, we decided to validate and characterize the effect of the 
selected top microRNAs under both anti-hypertrophic and pro-hypertrophic conditions, 
in order to assess the ability of each microRNA to counteract or induce the hypertrophic 
phenotype.   
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First, we investigated the effect of each microRNA on the expression of a set of genes 
previously associated with either pathological hypertrophy (foetal cardiac gene 
program: NPPA, NPPB, MYH7 and ACTA-1)  (reviewed in ref. [11]) or to physiological 
hypertrophy (ATP2a2, MYH6 and RYR ) (Figure 7, panel B). In particular, to examine the 
effect of microRNAs able to decrease CM cell size, we stimulated the cells with 
phenylephrine (PE), a known pro-hypertrophic stimulus, and simultaneously transfected 
them with individual microRNAs. In parallel, to test the effect of microRNAs able to 
increase CM cell size, the cells were starved (0.1% FBS) and transfected with the 
individual microRNAs. In all cases, total RNA was extracted 72 hours after transfection 
and analysed by qRT-PCR using TaqMan probes specific for the abovementioned subset 
of genes (experimental scheme Figure 7, panel A). 
The pure effect of PE (40 μM) on rat CMs cultured in 0.1% FBS was evaluated after 72 
hours of treatment, in the absence of microRNAs, by both qRT-PCR (Figure 7, panel C) 
and immunofluorescence (α-actinin, ANP) (Figure 7, panel B). PE strongly upregulated 
the subset of genes typical of the foetal cardiac gene program (NPPA, NPPB and ACtA1) 
and significantly increased CM size compared to the control. All the anti-hypertrophic 
microRNAs were able to revert the signature of pathological hypertrophy induced by PE 
by reducing the levels of ANP and BMP. However, only hsa-miR-1255, hsa-miR-1288, 
hsa-miR-509-3p and hsa-miR-665 were simultaneously able to significantly upregulate 
Myh6, Serca2a, and RyR, two known markers of good contractility (Figure 7, panel B 
and C)[18, 19]. The validation experiments confirmed that all the pro-hypertrophic 
microRNAs were able to increase CM cell size (Figure 7, panels E, F). In addition, all the 
selected microRNAs, with the exclusion of hsa-miR-29b, did not induce reactivation of 
the foetal gene program (Figure 7, panels E, F). On the other hand, overexpression of 
hsa-miR-29b remarkably increased both cell area and ANP when compared to the 
control (Figure 7, panel E). Accordingly, the qRT-PCR results showed a strong activation 
of the foetal gene program (increased ANP, BNP and skeletal α-actin) and reduced levels 
of SERCA2a and RYR, thereby displaying the typical molecular signature of pathological 
hypertrophy (Figure 7, panel F).  
Due to the epidemiological relevance of cardiac hypertrophy as a landmark of cardiac 
pathology, we decided to focus the subsequent research on anti-hypertrophic 
microRNAs and, in particular, to explore their capability to block and/or revert 
pathological hypertrophy. 
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To understand whether the identified microRNAs also modulate cell size of CMs from 
another species, thus increasing the probability of the conservation of their functional 
effect in human cells, we re-tested the selected 6 anti-hypertrophic microRNAs in 
neonatal mouse CMs. For these experiments, we evaluated the effect of selected anti-
hypertrophic microRNAs against the pro-hypertrophic effect of foetal bovine serum 
(FBS).  As reported by Bass et al. [199], FBS, which contains a wide range of different 
growth factors, induces the largest increase in CM cell area compared to other pro-
hypertrophic stimuli such as insuin growth factor 1, isoproterenol and PE. As reported in 
Figure 8 panel A, we transfected mouse primary CMs after 24 hours of starvation and 
simultaneously treated the cells with 5% FBS.  Seventy-two hours after transfection, 
cells were fixed and immuno-stained for α -actinin and ANP. Image segmentation and 
analysis was performed to selectively quantify cell size and number of ANP-positive 
CMs. As displayed in Figure 8 panel B and C, hsa-miR-665 scored the best in reducing 
CM cell area and significantly decreasing the percentage of ANP-positive CMs compared 
to CMs transfected with MC4.  
Based on these results, next we decided to individually test the effect of hsa-miR-665 in 
vivo in a model of hypertrophic response to transverse aortic constriction-induced (TAC-
induced) pressure overload. 
 
3.3 Hsa-miR-665 counteracts the onset of hypertrophy and preserves 
cardiac function after transverse aortic constriction 
To evaluate the anti-hypertrophic effect of hsa-miR-665 in vivo, we chose to investigate 
whether this microRNA was able to prevent development of hypertrophy in a TAC 
model of chronic cardiac pressure overload. Eight-week-old CD1 mice were subjected to 
TAC or sham surgery and, simultaneously, the mice were injected in the left ventricle 
anterior wall (LVAW), using AAV9 vectors expressing hsa-miR-665 or a control vector 
expressing an empty cassette (AAV9-Control) (1×1011 vg/animal; n=10 per group; 
Figure 9, panel A). Our previous experience indicates that this procedure results in 
efficient myocardial transduction and month-long expression of the transgene [133].  As 
reported in Figure 9 panel B, gross anatomic differences are appreciable across 
treatments. In particular, the overexpression of hsa-miR-665 successfully counteracted, 
at both 30 and 60 days, the hypertrophic remodelling of the heart thus maintaining the 
heart mass at physiological levels (30 days after TAC heart mass (gr) normalized on tibia 
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length (mm) was 0.09±0.020; compared with 0.13±0.019 for the animals that received 
the control vector, P<0.001; at 60 day after TAC, 0.010±0.0006 for AAV9-miR-665 
injected animals and 0.015±0.0008 for the animals that received the AAV9-Control 
P<0,.01. (Figure 9, panel C). 
Periodic Acid-Schiff (PAS) staining revealed a marked reduction in CM cross sectional 
area at 30 days after TAC (242.26±76.02 μm 2 for AAV9-miR-665 injected animals; 
compared with 487.26±104.27 μm 2 for the animals that received the AAV9-Control, 
P<0.001), different from what observed at 60 days after TAC where no significant 
differences between treated and control were measured (Figure 9, panel D).  
Masson’s trichrome staining, at day 30 and 60, revealed both a marked reduction in in 
tissue fibrosis in AAV9-miR-665 injected animals compared to AAV9-Control treated 
animals (Figure 9, panel E). 
As evaluated by echocardiography (echo) at 15, 30 and 60 days after TAC, LVAW 
thickness was significantly decreased in the treated mice with respect to controls at 
both 30 and 60 days. At 30 days after TAC, AAV9-miR-665-injected animals showed a 
LVAW thickness-s of 1.01±0.05 mm; compared with 1.36±0.65 mm for the animals that 
received the AAV9-Control, P<0.01 and the effect was maintained up to 60 day after 
TAC, 1.02±0.15 mm for AAV9-miR-665 and 1.44±0.8 mm for control treated animals 
(Figure 9, panel F).  Even more interestingly, at 30 and 60 days after TAC, left ventricular 
ejection fraction (LVEF) was also markedly preserved in constricted mice treated with 
AAV9-miR-665 compared to control animals. (Figure 9, panel G) (30 days after TAC LVEF 
of AAV9-miR-665 injected animals scored 56.5±5.4 compared to  42.54±5.90% in AAV9-
Control treated animals, P<0.05;  at 60 days after TAC LVEF of AAV9-miR-665 injected 
animals scored 51.3±5.8 compared to  34.82±0.77% in AAV9-Control treated animals, 
P<0.01).  Besides, no significant differences were observed in left ventricular internal 
diameter (LVID) measurements between treated and control groups (Figure 9, panel H).  
Taken together, these results indicate that the over-expression of hsa-miR-665 after 
aortic banding exerts a beneficial effect in reducing cardiac hypertrophy and preserving 
cardiac function in a chronic cardiac overload model, consistent with the effect that this 
microRNA had shown in vitro. 
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3.4 miR-665 delays cardiac dilatation and dysfunction in hypertrophic 
hearts  
Focusing on a possible translational application of these results, next we decided to 
verify whether hsa-miR-665 was able to revert established cardiac hypertrophy to 
normal phenotype and function. In this rescue experiment, mice were injected in the 
LVAW 2 weeks after TAC surgery with AAV9-hsa-miR-665 (1×1011 vg/animal; 10 weeks 
old female CD1 mice, n=8 per group). Using echo to determine LWAV thickness at 15 
days after TAC, animals were homogeneously grouped and then followed at day 30, 45 
and 60 (experimental scheme in Figure 10, panel A). While no significant rescue of the 
mild hypertrophic phenotype was observed during follow up (at day 15/30 post AAV 
injection - 45 and 60 post TAC, LVAW thickness: 0.88±1.13/0.91± 0.08 mm for AAV9-miR-
665 treated animals, compared to AAV9-Contol injected mice with 0.8±0.11/0.96±0.33 
mm), LV diastolic diameter and ejection fraction was strongly maintained in normal 
ranges in the treated animals in respect to controls (LVEF at final time point: 57.5%±5.60 
vs. 28.4%±15 in treated and control animals respectively, P<0.001; LVID at final time: 
4.05±0.16mm 4.8±0.69mm in treated and control animals respectively, P<0.001) (Figure 
10 panel F,G and H). 
Consistently, hsa-miR-665-treated mice showed the highest survival curve during the 2 
months follow up (data not shown).  At day 60 after TAC, mice were sacrificed and the 
hearts examined. Gross anatomy examination revealed a marked myocardial fibrosis 
with left ventricular dilatation and wall thinning in animals, which had received the 
control vector (Figure 10, panel B and E). It has to be acknowledged that thinned 
fibrotic segments may be responsible of partially unreliable M-Mode measurement of 
LVAW thickness.  In fact, analysis of PAS-stained heart cross sections in non fibrotic areas 
revealed no significant differences in CM cross sectional area between treated versus 
control animals (Figure 10, panels C and D). 
 Comprehensively, these results are consistent with a beneficial effect of the tested 
microRNA: LV dimensions and function were maintained in normal ranges in treated 
mice despite the harsh surgical model characterized by high mortality and detrimental 
LV remodeling in AAV9-control treated mice.  
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3.5 The transcriptomic signature of AAV9-miR665 overexpression in a 
transverse aortic constriction (TAC) model of chronic cardiac pressure 
overload. 
To identify the relevant targets of has-miR-665, we assessed global transcriptome 
changes by in vivo deep-sequencing of total heart RNA after TAC and transduction with 
AAV9-hsa-miR-665 or AAV9-Control (Figure 11, panel A). We calculated, using EdgeR, 
the biological coefficient of variation across replicates, which represents the extent of 
variability in relation to the mean of the distribution.  
The BCV plot in Figure 11 panel A reports the results of the analysis, which showed a 
coefficient of biological variation across the replicates of 0.2 (this value indicates that 
the true abundance for each gene can vary up or down by 20% between replicates). 
We assumed the following conditions as starting data for rnapower function [197]: 1) 
Number of 3 replicates per condition (AAV9-miR665 upon TAC, AAV-CTRL upon TAC 
and sham-operated animals); 2) Coefficient of Variation= 0.2 ; 3) P-Value≤0.05. We 
estimated as optimal non statistical thresholds 10 normalized FPKM/gene (Fragments 
Per Kilobase Of Exon Per Million Fragments Mapped) and 1 absolute Logarithmic base 2 
fold change fo down/up regulation (Figure 11, panel B).  
RNAseq data were also processed with pvclust (Figure6, panel C), which is an R package 
for assessing the uncertainty in hierarchical cluster analysis. For each cluster in 
hierarchical clustering, quantities called p-values are calculated via multiscale bootstrap 
resampling. The p-value of a cluster is a value between 0 and 1, which indicates how 
robustly the cluster is supported by the data. This analysis provides two types of p-
values: AU (Approximately Unbiased) p-value and BP (Bootstrap Probability) value. 
Clusters with AU larger than 95% are highlighted by red rectangles, showing that these 
are strongly supported by data. As reported in Figure 11 panel C, the group of TAC-
mice injected with AAV9-hsa-miR665 clustered together with sham-operated animals. 
This evidence strongly supports the fact that the overexpression of hsa-miR-665 
massively counteracts TAC-induced hypertrophy, leading to an mRNA signature not 
statistically significantly different to that of a healthy heart. 
This analysis identified 67 down-regulated transcripts (FPKM≥10, FDR≤ 0.05) and 83 up-
regulated mRNAs (FPKM≥10, FDR≤ 0.05) (Figure 12, panel A). Interestingly, the mRNAs 
most up-regulated in TAC+AAV9-Control animals were also the transcripts most down-
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regulated in the TAC+hsa-miR-665 group, supporting the ability of hsa-miR-665 to blunt 
the hypertrophic phenotype (Figure 12, panel B).  
Among the mRNAs found to be the most down-regulated, we sought to identify those 
responsible for controlling CM cell size. We individually knocked down 43 of these 
mRNAs, for which short interfering RNAs were available, under conditions similar to 
those of the initial screening. Mouse CMs were prepared from P0 mice and reverse 
transfected with the library of selected siRNAs. After 52 hours, EdU was added and 20 
hours later cells were fixed and stained for α-actinin and EdU (experimental scheme 
Figure 12, panel C). Five of these siRNAs (targeting Cdc42, RRP7A, Desmin, Enah and 
Smpd2) had an effect on cell size which was comparable (less than 2 standard 
deviations compared to has-miR-665) to that induced by hsa-miR-665 overexpression 
(Figure 12, panel D). Enah and Cdc42 were the only two genes that were also down-
regulated more than 2 fold after the over-expression of has-miR-665 in vivo (Figure 12, 
panel E).  In particular, Enah is a downstream effector of cdc42 and is necessary for 
cdc42/IRSp53-induced actin polymerization [200]. Moreover, Enah cooperates with N-
Wasp and WAVE2 in promoting F-actin polymerization under the stimulation of IGF1, a 
known pro-hypertrophic stimulus [201] [202]. In addition, the cardiac overexpression of 
Enah leads to a marked hypertrophic phenotype [203]. 
Further analysis identified two additional genes (Xirp2 and Fhl1) that are not only 
known to play a role in cardiac hypertrophic but are also functionally connected to 
Enah. These genes were also strongly down-regulated in the mRNA-seq dataset (Figure 
12, panel E) and the same results were obtained by confirmation experiment using qRT-
PCR. When knocked-down individually, however, the siRNAs against Xirp2 and Fhl1 were 
individually inefficient at reducing cell size in vitro (Figure 7, panel D), suggesting that 
the effect of their down-regulation might become apparent only when other genes also 
simultaneously repressed. 
3.6 Luciferase 3’-UTR reporter assay to validate direct targets of hsa-
miR-665 
We decided to focus our attention on three hits: Enah, Xirp2 and FHL1. All these 
transcripts encode for proteins that localize in the proximity of the intercalated discs. 
Here they integrate and transduce multiple mechanical stimuli, thereby promoting 
cardiac hypertrophic remodelling both at a transcriptional and a structural level [89, 
203-205]. The question that we wanted to address was whether these transcripts are 
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direct targets of hsa-miR-665. Since the in vivo study and the subsequent mRNAseq on 
total heart was performed by overexpressing a human microRNA in a mouse 
background, we decided to analyse the predicted targets of both hsa-miR-665 and 
mmu-mir-665-3p (ortholog in mouse) in their respective species background. Figure 13 
panel A reports the result of the above-mentioned analysis run with the bioinformatic 
tool RNA22 (Computational Medicine Center of Thomas Jefferson University). We were 
able to identify positive matches for hsa-miR-665 in the human transcripts of all three 
candidates, however only the mouse transcript of Xirp2 scored positively also for mmu-
miR-665-3p.  
We are well aware of the poor predictive capacity of virtually any currently available 
software or software combination aimed at predicting microRNA targets. For this 
reason, and due to the discordance of the predictions obtained, we decided to 
manually check for canonical site types, such as:  -­‐ 8mer: match to microRNA positions 2–8 with an A opposite position 1 [206]; -­‐ 7mer-m8 site: position 2–8 match[206] -­‐ 7mer-A1 site: position 2–7 match with an A opposite position 1 [206] -­‐ 6mer: position 2–7 match [206] [207]; -­‐ offset-6mer: position 3–8 match [206] [207]. 
As reported in Figure 13 panel B, we found that Fhl1 has three offset-6mer sites (two 
sites are present in the 3’UTR and 1 site in the 5’UTR), Enah has 4 offset-6mer sites in the 
3’UTR while Xirp2, in accordance with the prediction, showed one 8mer match in the 
5’UTR.  
In order to validate these potential microRNA target sequences, four constructs were 
generated by cloning the complete sequence of the 3’ UTR and 5’UTR of Fhl1, 5’UTR of 
Xirp2 and a portion of the 3’UTR of Enah into the reporter vector psiCHECK-2 (Promega) 
(Figure 13, panel C).  In this construct the expression of Renilla-luciferase is modulated 
by the binding of the microRNA to its targets, while the expression of Firefly-luciferase is 
used as reference.  
As reported in Figure 14 panel A, we reverse transfected HeLa cells with hsa-miR-665 
(50 nM final concentration) and, after 24 hours, the medium was changed and cells 
were transfected with one of the four different constructs. Forty-eight hours after, cells 
were lysed and both Renilla-luciferase and Firefly-luciferase activity were measured 
using the Dual-Glo luciferase assay system (Promega). The Renilla-luciferase expression 
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was then normalized on Firefly-luciferase for each of the samples and then expressed as 
fold change over MC1. The results of the assay (Figure 14, panel C) clearly indicate that 
hsa-miR-665 was able to target the 3’UTR of Fhl1, the 5’UTR of Xirp2 and the 3’UTR of 
Enah. 
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4.1 Discussion 
In this research project, the screening of 875 microRNA mimics using a fluorescence-
microscopy-based, high-throughput assay in NRVCMs led to the identification of a 
previously uncharacterized anti-hypertrophic microRNA, hsa-miR-665.  Our experiments 
revealed that this microRNA is able to turn off the foetal cardiac gene program and to 
upregulate Myh6, Ryr and Atp2a2 in NRVCMs upon stimulation with PE, a strong α 1-
adrenergic receptor agonist, known to mimic the molecular signature of pathological 
cardiac hypertrophy.  In particular, pathological cardiac hypertrophy is known to be 
associated with the upregulation of foetal genes, such as Nppa, Nppb, Myh7 and Acta-1 
and the downregulation of Atp2a2 Myh6 and Ryr (reviewed in ref. [11]). The switch in 
myosin isoforms is commonly considered a marker of the failing heart, nevertheless it 
represents an adaptive response to pathological stimuli, since βMHC, which is encoded 
by Myh7, is slower in catalysing ATP-hydrolysis, thus allowing a less powerful but more 
energy-saving contractile function [208] [209] [210].  The same concepts can be applied 
to the increased production of the natriuretic peptides ANP and BNP, encoded by Nppa 
and Nppb genes respectively. ANP and BNP are highly increased in the failing heart; 
clinically, plasma levels of BNP are used as diagnostic and prognostic markers for 
hypertrophy and HF in human patients [211].  Once released in the blood flow, these 
peptides exert a plethora of systemic effects aimed at unloading the failing heart, 
including antagonism of the renin-angiotensin system, increase in renal natriuresis and 
diuresis and vasodilatation (reviewed in ref. [212]). 
The re-activation of foetal genes and the switch in contractile protein isoforms does not 
occur in physiological hypertrophy (mainly induced by exercise), despite a remarkable 
increase in protein production and consequent cellular growth (reviewed in ref. [11]). 
This evidence suggests that the contribution of this subset of foetal genes to the 
pathophysiology of cardiac hypertrophy is not well understood. Despite these 
uncertainties, it is broadly established that a prolonged condition of cardiac 
hypertrophy is characterized by the upregulation of Nppa, Nppb, Myh7 and Acta-1 and 
leads to a detrimental cardiac remodelling. The expression of these genes was 
normalized upon delivery of hsa-miR-665. 
Our results also indicated that hsa-miR-665, formulated as an AAV9 vector, significantly 
blunted the hypertrophic phenotype in hearts submitted to chronic pressure overload 
(8 weeks of TAC), when the vector was administered simultaneously to aortic banding. 
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Treatment with AAV9-hsa-miR-665 increased animal survival during the 2 month follow 
up (data not shown) and effectively preserved cardiac function under chronic pressure 
overload. This was best seen by the echocardiographic analysis of left ventricular 
ejection fraction, which, 60 days after TAC, was 33% higher in microRNA-treated animals 
compared to controls. 
In addition, hsa-miR-665 showed a remarkable therapeutic effect by blocking 
pathological cardiac remodelling and preventing heart failure in hearts submitted to 
chronic pressure overload (8 weeks of TAC). In this model, the microRNA was 
administered 15 days after aortic banding, again formulated as an AAV9 vector. The 
treatment with hsa-miR-665 was not able to revert the mild-hypertrophic phenotype 
developed during the first 15 days of pressure-overload but it effectively prevented the 
treated hearts from developing HF by blocking left ventricular dilation and preserving 
cardiac ejection fraction (after 8 weeks of TAC: LVEF scored 50% higher in treated 
animals compared to controls).  The key message of the results of this rescue 
experiment is that hsa-miR-665 not only has to be considered as an anti-hypertrophic 
agent but also that its effect has the potential to extend to a broader range of 
pathological conditions, aiming at the improvement of cardiac function in the presence 
of pathological cardiac remodelling.  
To understand the mechanisms of action of hsa-miR-665, we decided to assess the 
global mRNA expression changes after TAC in hearts transduced with the AAV9 
expressing this microRNA or an AAV9-Control. Particular attention was paid to the 
genes that were downregulated, which should include all direct and indirect targets of 
the microRNA. Subsequently, the most downregulated mRNAs were individually 
silenced in NMVCMs and the cell size was automatically measured.  
Understanding the mRNA targets of a given microRNA is commonly considered a very 
challenging task. In this respect, bioinformatics algorithms are of little help, since the 
capacity of these algorithms, even when used collectively, is relatively poor in 
predicting the mRNAs that are really downregulated in vivo by the microRNA. One 
powerful method to assess microRNA target function is to explore the changes of the 
transcriptome in response to cell treatment with the microRNA, focus on 
downregulated genes (which include direct targets, in addition to indirect ones), and 
then verify whether any of these targets, once downregulated by specific siRNAs, mimic 
the phenotype imparted by the microRNA itself.  
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When siRNAs against the genes downregulated by hsa-miR-655 treatment were 
individually tested, we observed that only five of these genes (Cdc42, Enah, Des, Rrp7a 
and Smpd2), when individually silenced, were able to mimic the effect of hsa-miR-665 in 
reducing cell size of NMVCMs. These genes were all downregulated in the 
transcriptome analysis even if only two (Cdc42 and Enah) scored less than -1Log2 fold, 
which was the limit of statistical significance set for our analysis, considering a false 
discovery rate ≤0.05 and 3 replicates per condition. In contrast, the genes that resulted 
most downregulated by the over-expression of hsa-miR-665 (i.e. Nppa, Ankrd1, Acta1, 
Xirp2 and Fhl1), when individually silenced, were either not or only slightly effective in 
reducing NMVCMs cell size.  
At this point two possibilities were equally probable: 1) the most-down regulated 
transcripts were off-targets 2) hsa-miR-665 modulates biological processes that cannot 
be effectively measured in vitro, such as mechanosensing and CMs compliance to 
stretch, by an individual siRNA knockdown. 
Further along the path of discovering functional hsa-miR-655 targets, we selected three 
candidates, namely Enah, Xirp2 and Fhl1.   
ENAH localizes in IDs and is a down-stream effector of CDC42. Both these genes are 
involved in actin filament elongation, thus regulating cellular morphology and polarity 
[213]. The function of Cdc42 in cardiomyocytes is still debated, although the 
overexpression of Cdc42 was reported to enhance CM hypertrophy in vitro [214]; 
nevertheless in 2009 Maillet et al. reported a novel anti-hypertrophic signalling pathway 
due to the CDC42-dependent, JNK activation, which antagonizes calcineurin-NFAT 
activity, thus reducing pathological hypertrophic cardiac remodelling [215].  
Only a few scientific reports describe the effect of Enah in the heart; the role of Cdc42 is 
equally unclear. On the one hand, Belmonte et al. have reported that the cardiac over-
expression of Enah leads to cardiac hypertrophy and promotes HF [203]. On the other 
hand, altered levels of Enah (upon either its over-expression or silencing) are associated 
with impaired connexin-43 localization, conduction abnormalities and dilated 
cardiomyopathy [216] [217]. This evidence suggests that the levels of Enah have to be 
finely tuned and that extreme variations in both directions are equally detrimental. 
Interestingly, the mRNA levels of Enah are upregulated by TAC and are restored at basal 
levels by treatment with has-miR-665 (data reported in Table 4 and Figure 12 panel G).  
 69 
Xirp2 is a member of the muscle-specific, actin-binding Xin gene family. Interestingly, 
the class of proteins encoded by this family of genes is expressed only in the four-
chambered heart of vertebrates (reviewed in [218]). In particular, all the proteins that 
belong to this family are characterized by the presence, at their N-terminus, of multiple 
copies of a conserved repeating unit of 16 amino acid residues (reviewed in [218]). In 
humans, two Xin repeat-containing proteins have been identified so far, namely XIRP1 
(Xin actin- binding repeat-containing protein 1) and XIRP2 (Xin actin- binding repeat-
containing protein 2). These proteins are encoded by two different genes, which were 
first identified as genes associated with cardiomyopathies, respectively named as 
cardiomyopathies associated gene 1 (CMYA1) and cardiomyopathies associated gene 3 
(CMYA3) [219] [220]. The orthologous genes in the mouse are Xinα and Xinβ 
respectively. The former codes for three different protein variants (XINA, XINB, 
XINC/XIRP1), while the latter codes for XIRP2 [221]. The common functional feature 
shared by the member of this class of proteins is the ability to bind actin filaments, 
hence the name XIRP. Moreover, both XIRP1 and XIRP2 were shown to selectively bind 
the SH3 domain of nebulette, which is known to be exposed and to actively recruit N-
WASP during myofibril formation and elongation [222] [223].  In addition, in the mouse, 
XIRP1 directly interacts with F-Actin and recruits ENAH, which in turn promotes 
myofibril formation exerting its “anti-capping” activity [224].  Finally, McCalmon et al. 
showed that XIRP2 is upregulated in pressure overload-induced cardiac hypertrophy 
and that its expression is regulated by Mef2a, a known pro-hypertrophic transcription 
factor [225] [226]. 
Even if a direct interaction between XIRP2 and ENAH has not been described yet, the 
aforementioned evidence on the role of XIRP1 in recruiting ENAH on F-actin together 
with the known upregulation of both ENAH and XIRP2 during pathological cardiac 
remodelling, are consistent in indicating a pivotal role of these proteins in complex 
sarcomeric remodelling under cardiac stress-response. 
FHL1 is a member of the four and a half LIM domain-only protein family, together with 
FHL2 and FHL3; expression of these proteins is particularly enriched in striated muscle 
[227]. These proteins are structurally characterized by four complete LIM domains and 
an N-terminal half LIM domain. LIM domain are protein-protein interaction domains, 
characterized by a cysteine rich motif that co-ordinately binds two zinc atoms and 
mediates protein-protein interactions [228].  Recent studies have shown that FHL1 is the 
only member of the FHL-protein family to be upregulated in mouse hearts after in vivo 
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pressure overload-induced hypertrophy as well as in the hearts of patients with 
hypertrophic cardiomyopathy, thus suggesting its involvement in pathological cardiac 
remodelling in both mouse and humans [229] [230]. Furthermore, work performed by 
Sheikh et al. led to the conclusion that FHL1 is a novel sensor of sarcomeric stretch. In 
particular, it was shown that FHL1 binds the N2B domain of titin and is responsible for 
stretch- or Gq-induced- activation of the MAPK cascade in pressure-overload-induced 
hypertrophy. FHL1 performs a scaffolding function, since direct interactions between 
FHL1 and Raf-mediated MAPK was shown to be fundamental in sustaining transduction 
of pro-hypertrophic stimuli [103]. Furthermore, FHL1 double KO mice showed increased 
LV-diastolic-compliance in TAC-induced hypertrophy, thus suggesting that, in the 
absence of FHL1, the N2B domain of titin adopts a more relaxed conformation [103].  
Taking our results together with the available literature evidence, we suggest a model 
(Figure 10) by which hsa-miR-655 exerts a triple role in modulating cardiac 
hypertrophy: 1) hsa-miR-655-induced down-regulation of Fhl1 eventually blocks 
transduction, into the nucleus, of pro-hypertrophic signals that rely on the Raf-
mediated MAPK cascade - these signals can include pressure-overload induced 
hypertrophy; 2) down-regulation of Fhl1 also eventually reduces ventricular wall-stress 
by the modulation of titin elasticity, thus protecting IDs morphology and preventing CM 
functional uncoupling; 3) hsa-miR-655-induced downregulation of Xirp2 and Enah 
eventually reduces the recruitment of Xirp2 and Enah to the IDs, where these proteins 
are known to promote myofibril formation.  At this point, further experiments are 
needed in order to evaluate the global effect of hsa-miR-665 over-expression in the 
heart. In particular, on the one hand it will be crucial to elucidate the effects, on CM 
biology, of all the other genes whose mRNAs resulted strongly down-regulated (≥2Log2 
fold) by hsa-miR-665 overexpression, namely Gm4841, Art3, Ankrd1 and Tesk1. On the 
other hand, we need to understand what is the effect of hsa-miR-665 overexpression in 
the two main other cardiac cell types, namely cardiac fibroblasts and endothelial cells. 
In addition, differential proteomic analysis (SILAC) has to be performed in order to 
identify the effect that hsa-miR-665 may directly exert at the translational level, by 
identifying differentially downregulated proteins.  
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4.2 Conclusions and future perspectives 
The results presented in this thesis indicate that hsa-miR-665 effectively reduces cell 
size of rat and mouse neonatal cardiomyocytes under strong pro-hypertrophic 
conditions and negatively regulates the expression of genes known to be associated 
with pathological cardiac remodelling (Nppa, Nppb, Myh7 and Acta-1). Moreover, hsa-
miR-665 blocks cardiac hypertrophy and pathological cardiac remodelling whilst 
increasing cardiac function, in a mouse model of left ventricular pressure overload. 
Finally, hsa-miR-665 acts therapeutically, in a mouse model of left ventricle pressure 
overload with established cardiac hypertrophy, by preventing left ventricular dilatation 
and heart failure thus increasing animals life span. 
These results not only reveal an important regulator of cardiomyocyte response to 
external stress, but also suggests means and targets for therapeutic intervention. Direct 
delivery of hsa-miR-665, either as a modified mimic RNA or in the form of an AAV vector, 
might be considered as a possible therapeutic strategy for pathological hypertrophy 
and, in particular, for HFpEF, a condition in which modulation of cardiac elasticity and 
down-regulation of stiffness are expected to provide important benefit.  
In addition to the direct use of hsa-miR-665 as a therapeutic molecule, this work has 
revealed a few targets of its action which could be exploited themselves for the 
generation of innovative small molecule therapeutics. Indeed, our results predict that 
the controlled, pharmacological inhibition of Flh1, Enah and Xirp2 would provide 
benefit to conditions of pathological cardiac hypertrophy and, again, HFpEF. More in 
general, the discovery of the beneficial effect of the down-regulation of these genes is 
an example of the powerful use of microRNAs as therapeutic tool in the treatment of  
cardiovascular disease. 
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FIGURE 1. The heart structure  
Adapted from Cardiac Tissue Structure, Properties, and Performance: A Materials Science Perspective. Ann Biomed Eng. 2014 Oct; 42(10): 2003–2013.
 Published online 2014 Aug 1. doi:  10.1007/s10439-014-1071-z
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FIGURE 2.  Pathological and physiological cardiac hypertrophy 
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FIGURE 3. Main pathways involved in cardiac hypertrophy 
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FIGURE 4.  MicroRNA biogenesis  
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FIGURE 5. Adeno associated virus.  
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FIGURE 6 High-content screening for microRNAs regulating 
cardiomyocyte cell size  
 80 
 
FIGURE 7. Validation of selected microRNAs in rat CMs 
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FIGURE 8. Validation of selected anti-hypertrophic microRNAs in 
mouse CMs 
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FIGURE 9. Overexpression of hsa-miR-665 in a TAC model of chronic 
pressure overload 
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FIGURE 10. Overexpression of hsa-miR-665 on established 
hypertrophic phenotype 
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FIGURE 11. mRNAseq analysis  
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FIGURE 12. The molecular signature of hsa-miR-665 
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FIGURE 13. Generation of luciferase reporter constructs for 3’UTR 
binding assay 
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FIGURE 14. Fhl1, Enah and Xirp2 are direct targets of has-miR-665. 
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FIGURE 15. The proposed mechanism of action for hsa-miR-665 
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FIGURE  LEGENDS 
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Figure 1. The structure of the heart. The heart is a muscular organ that pumps blood 
through the circulatory system.  In mammals, it is composed of four chambers: upper 
left and right atria; and lower left and right ventricles. Myocardium is the contractile 
portion of the heart and it is mainly composed of CMs. The contractile activity of CM is 
based on sarcomeres, which can be defined as highly ordered arrays of thick- and thin- 
filaments. The sarcomere can shorten its length, under increased level of cytoplasmic 
Ca2+, thus allowing the CMs to undergo cycles of contraction and relaxation in a Ca2+ 
dependent manner. IDs, which couple CMs activity, permit a coordinated and efficient 
contraction. (adaoted from [231]) 
 
Figure 2. Concentric and eccentric hypertrophy Pressure overload induces 
concentric hypertrophy by the thickening of the left ventricle wall. Volume overload 
induces an increase in muscle mass via the addition of sarcomeres in series, leading to 
eccentric hypertrophy. Both concentric and eccentric hypertrophy are in the beginning 
to be considered as adaptive and, if the stimulation is prolonged, both induces 
pathological cardiac remodelling and heart failure (adapted from [11]). 
 
Figure 3.  Main pathways involved in cardiac hypertrophy. 
A schematic and simplified representation of the major signalling pathways involved in 
pathological and physiological cardiac hypertrophy. It has to be considered that the 
molecular mechanism at the basis of cardiac hypertrophy are relying on the integration 
of multiple signalling cascades and due to their intrinsic complexity is difficult to 
generate an all encompassing scheme. 
 
Figure 4. The microRNA processing pathway. This figure reports a schematic 
representation of the microRNA processing pathway. Into the nucleus, primary 
microRNA are transcribed by RNA polymerase II or III and cleaved by the microprocessor 
complex Drosha–DGCR8 (Pasha), thus generating a pre-microRNA. The pre-microRNA, is 
transported by Exportin-5 from the nucleus into the cytoplasm, where the RNase Dicer 
in complex with TRBP cleaves the hairpin and generates a dsRNA of 20-22 nucleotide 
termed as mature microRNA. The functional strand of the mature microRNA is loaded 
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together with Ago2 into the RISC complex. Once loaded, it targets the RISC complex to 
silence specific transcripts. 
 
 
Figure 5.  Adeno Associated Virus. A, genome structure. B, Schematic representation 
of wt-AAV and r-AAV genome structure. C, Schematic representation of the strategy 
used for the production of rAAV vectors expressing a given gene. 
 
Figure 6. High-content screening for microRNAs regulating CM cell size.  A, 
Screening workflow; B-C, reverse transfection efficiency of rat CMs. Rat CMs were 
reverse transfected with a toxic siRNA (siRNA targeting Ubiquitin C), and fixed 72 hours 
later. Nuclei were stained with Hoechst and quantified automatically; D, CM area in μm2 
following transfection with 875 microRNAs; approximately 2500 cells were analysed per 
microRNA/replicate, Ctrl dashed line correspond to CMs transfected with MC4; 
Correlation between two screening replicates: Spearman coefficient 0.84; E, Correlation 
between CM size and percentage of proliferating cells following treatment with the 875 
microRNAs, Ctrl dashed line correspond to CMs transfected with MC4; F, list of selected 
microRNAs modulating CM cell size; G, Microscopy images (α-actinin, EdU, Nuclei) and 
image reconstruction of rat CMs treated with control MC4, hsa-miR-665 and has-miR-
664-5p. Values show mean±SD of two independent screenings conducted on two 
independent mouse CM preparations.  
 
 
Figure 7. Validation of selected microRNAs in rat CMs. A, Experimental model; B, 
Known molecular signature of pathological vs physiological hypertrophy; C, 
Immunostaining (α-actinin, ANP, Nuclei) of rat CMs treated with selected anti-
hypertrophic microRNAs stimulated with 40 μ M PE; D. qRT-PCR results of rat CMs 
treated with selected anti-hypertrophic microRNAs stimulated with 40 μ M PE; E, 
Immunostaining (α-actinin, ANP, Nuclei) of rat CMs treated with selected pro-
hypertrophic microRNAs; F. qRT-PCR results of rat CMs treated with selected anti-
hypertrophic microRNAs stimulated with 40μM PE. Values show mean±SD of three 
independent experiments conducted on three independent mouse CM preparations.  
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. All conditions were compared to PE-treated CMs using unpaired t-test. *P<0.05, 
**P<0.01, ***P<0.001 
Figure 8. Validation of selected anti-hypertrophic microRNAs in mouse CMs. A, 
Experimental model; B, CM area and ANP positive cells, fold change over CTRL (control 
microRNA#4) following treatment with the selected anti-hypertrophic microRNAs, 
approximately 2500 cells were analysed per microRNA/replicate; C, Immunostaining (α-
actinin, ANP, Nuclei) of mouse CMs treated with MC4, hsa-miR-665 and hsa-miR-1255a. 
Values show mean±SD of three independent experiments conducted on three 
independent mouse CM preparations. All conditions were compared to CTRL using 
unpaired t-test. *P<0.05, **P<0.01, ***P<0.001 
 
Figure 9. Overexpression of hsa-miR-665 in a TAC model of chronic pressure 
overload. A, sham surgery or thoracic aortic constriction (TAC) was performed in 10 
weeks old female CD1 mice. At the same time mice (n=8), which received TAC surgery, 
were injected with AAV9-hsa-miR-665 or an AAV9 control  (1×1011 vg/animal). Heart 
function was analysed by echocardiography at 15, 30 and 60 days post-TAC, and mice 
were sacrificed at days 30 or 60 post-TAC for histological analysis. B, Whole heart 
images for sham, AAV9-Empty, AAV9-hsa-miR-665 30 and 60 days after TAC. C, Heart 
mass, reported as ratio of heart weight to tibia length for sham, AAV9-Empty, AAV9-hsa-
miR-665, 30 and 60 days after TAC.D, qRT-PCR on premiR-hsa-665 expression levels 
expressed as absolute number of molecules. E, Periodic acid–Schiff (PAS) staining of 
heart sections from mice with the same treatment as in panel B (scale bar, 50 μm). 
Graphs at right show quantification of cell size as cell surface area. F, Masson trichromic 
staining of heart sections from mice treated as in panel B. Echocardiography 
measurement of LVAWd - Left Ventricle Anterior Wall thickness during Diastole (G), EF - 
Ejection Fraction (H), LVID - Left Ventricle Internal Diameter (I) at 30, 45 and 60 days 
after AAV-control or AAV-miR-665 intra-cardiac injection (1×1011 vg/animal). Values 
represent a mean±SD; n=8animals/group. Two-way ANOVA, Tukey’s post-hoc comparison 
tests  *P<0.05, **P<0.01, ***P<0.001.. 
 
Figure 10. Overexpression of hsa-miR-665 on established hypertrophic 
phenotype. A, sham surgery or thoracic aortic constriction (TAC) was performed in 10 
weeks old female CD1 mice. 15 days after TAC mice (n=8), which received TAC surgery, 
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were injected with AAV9-hsa-miR-665 or an AAV9 control. heart function was analyzed 
by echocardiography at 30, 45 and 60 days post-TAC, and mice were sacrificed at days 
45 or 60 post-TAC for histological analysis. B, Whole heart images for AAV9-Empty and 
AAV9-hsa-miR-665 60 days after TAC (n=8 per group). C , PAS staining of  heart sections 
from mice treated with AAV9-Empty and AAV9-hsa-miR-665 45 and 60 days after TAC 
(scale bar,50 μm). Graphs at right show quantification of cell size as cell surface area (D). 
E, Masson tricromic staining of heart section from mice treated as in panel C. 
Echocardiography measurement of LVAWd - Left Ventricle Anterior Wall thickness 
during Diastole (F), EF - Ejection Fraction (G), LVID - Left Ventricle Internal Diameter (H) 
at 30, 45 and 60 days after AAV-control or AAV-miR-665 intra-cardiac injection (1×1011 
vg/animal). Values represent a mean±SD; n=8animals/group. Two-way ANOVA, Tukey’s 
post-hoc comparison tests *P<0.05, **P<0.01, ***P<0.001. 
 
Figure 11. mRNAseq. A. Determination of the coefficient of variation across 
replicates. B, Rnapower analysis with the biological coefficient of variation. y-axis is 
reports the number of replicates per group, x-axis reports the coeeficient of variation. 
Green dashed line indicates the number of replicates used (n=3) and the estimated BCV 
of 0.2. C, Hierarchical cluster analysis using Ward-D method: in red boxes are the 
samples that resulted in significant clustering (AU≥95%). 
 
Figure 12.  The molecular signature of hsa miR-665. A, Log2 Fold change of mRNA 
up/down regulated in TAC-mice injected with AAV9-hsa-miR-665 (n=3) over TAC-mice  
injected with AAV9-Ctrl (n°=3); B, The mRNA most upregulated in TAC-mice injected 
with AAV9-Ctrl (n=3) are the most down-regulated following overexpression of AAV9-
hsa-miR-665; C siRNA screening workflow; D, Effect on mouse CM cell size of selected 
siRNAs. F, Alpha-actinin and EdU staining of mouse primary CMs treated with hsa-miR-
665 and selected siRNAs: Enah, Fhl1 and XIrp2; G, Validation of the mRNA level of 
expression of  Enah, Fhl1 and Xirp2 by qRT-PCR, same experimental condition as in A. 
Values represent a mean±SD; n=3 animals/group. Two-way ANOVA, Tukey’s post-hoc 
comparison tests *P<0.05, **P<0.01, ***P<0.001. 
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Figure 13. Generation of luciferase reporter constructs for 3’UTR binding assay. 
A, Comparison between the predicted sequences (RNA22 computational tool by the 
Computational medicine centre of Thomas Jefferson University) targeted either by hsa-
miR-665 or mmu-miR-665-3p in the UTRs of Fhl1, Xirp2 and Enah; B, Seed sequences of 
hsa-miR-665 and mmu-miR-665-3p, and the list of matches found in the UTRs of the 
selected candidate targets; C, UTR cloning strategy into psi-CHECK2-Vector (Promega); 
D, Gel electrophoresis (1.5 % agarose) of the reporter constructs generated as in panel C 
and digested with XhoI and NotI in order to verify correct cloning. 
 
Figure 14. Fhl1, Enah and Xirp2 are direct targets of has-miR-665. A, Experimental 
scheme. B, Reporter vector. C, 3’-UTR luciferase reporter assays performed in HeLa cells 
transfected with MC1(cel-miR-67) or hsa-miR-665. Results are shown for the 3’-UTRs of 
Fhl1, Enah and for the 5’UTRs of Fhl1 and Xirp2, as well as for the empty vector (Vector); 
Renilla luciferase activity was normalized to that of firefly luciferase. Values represent a 
mean±SD of three independent experiments. All conditions were compared to cel-miR-
67 using unpaired t-test. *P<0.05, **P<0.01, ***P<0.001 
 
Figure 15. The proposed mechanism of action for hsa-miR-665 
The hsa-miR-655-induced downregulation of Fhl1 blocks the pro-hypertrophic signals 
(i.e. pressure-overload induced hypertrophy or ANGII induced hypertrophy) that rely on 
phosphorylated ERK2. The downregulation of Fhl1 increases titin elasticity, thus 
reducing ventricular wall-stress and consequently protecting IDs morphology and CM 
functional coupling. The hsa-miR-655-induced downregulation of Xirp2 and Enah 
reduces the recruitment of Xirp2 and Enah to the IDs, where these proteins are known to 
promote myofibril formation during cardiac hypertrophic remodelling. 
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Table 1. List of reagents 
List of reagents Supplier 
Anti alpha-actinin antibody Abcam 
iQ Supermix BIO-RAD 
Masson’s trichrome staining kit BioOptica 
Anti connexin-43 antibody   
35 mm primaria tissue culture dishes CORNING 
100 mm primaria tissue culture dishes CORNING 
microRNAs mimic Dharmacon 
siRNAs smart pool Dharmacon 
siRNA/microRNA resuspension buffer Dharmacon 
Transparent 96 multiwell tissue cultured plates Falcon 
T75 tissue cultured flasks Falcon 
T175 tissue cultured flasks  Falcon 
DMEM, low glucose, GlutaMAX™ Supplement, pyruvate   Gibco 
DMEM, high glucose, GlutaMAXª Supplement, pyruvate  Gibco 
Foetal calf serum Gibco 
Primer and Oligos Integrated DNA Technology 
gBLOCKs Integrated DNA Technology 
RNAiMax Invitrogen 
TRIZOL Invitrogen 
Hoechst 33342 Life Technologies 
Nucleobond Xra Maxi Machery Nagel  
Anti ANP antibody Millipore 
100 mm tissue cultured dishes NEST 
Restriction Enzymes NewEnglandBiolabs 
ViewPlate-96 Black, Optically Clear Bottom, Tissue Culture Treated, Sterile PerkynElmer 
CellCarrier-384, Black, Ultra Microplates, Collagen type 1-coated, Sterile PerkynElmer 
OptiPlate-96, White Opaque 96-well Microplate PerkynElmer 
FuGENE HD Promega 
Dual-Glo Luciferase Assay System Promega 
Wizard SV MiniPrep system Promega 
RNeasy mini kits  Quiagen 
bovine serum albumin (BSA) Roche 
Vitamin B12 Sigma 
Trypsin Sigma 
penicillin/streptomycin  Sigma 
Phenyephryne Sigma 
PARAFORMALDEHYDE Sigma 
Tryton X-100  Sigma 
PAS staining kit  Sigma 
Eukitt mounting medium  Sigma 
Eukitt mounting medium  Sigma 
Ethanol Sigma 
Chloroform Sigma 
Taqman probes for qRT-PCR Thermo Fisher  
Click-IT EdU 594 Imaging kit  ThermoFIsher 
EdU ThermoFIsher 
ALEXA-594-α-mouse ThermoFIsher 
ALEXA-488-α-mouse ThermoFIsher 
ALEXA-594-α-Rabbit ThermoFIsher 
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Table 2. List of TaqMan probes 
 
 
  
Gene Probe 
NPPA (FAM)-RN00664637_g1 
NPPB (FAM)-RN00676450_g1 
MYH7 (FAM)-RN001488777_g1 
ACTA-1 (FAM)-RN00570060_g1 
ATP2A2 (FAM)-RN00568762_m1 
MYH6 (FAM)-RN01489272_g1 
RYR (FAM)-RN01470303_m1 
FHL1 (FAM)-Mm04204611_g1 
XIRP2 (FAM)-Mm01335343_m1 
ENAH (FAM)-Mm00468746_m1 
GAPDH (FAM)-Rn99999916_s1 
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Table 3. List and sequences of cherry picked mouse siRNAs 
Gene Symbol Gene Id Sequence 
1110014J01RIK 74778 GAAGUAGACGCAUUCAUGG 
1110014J01RIK 74778 GCGGAAUUCACAAGUGGAU 
1110014J01RIK 74778 GCUUUCAGGUAGCUUAUGU 
1110014J01RIK 74778 UAAAUUCCGACCCUACUGA 
1110032E23RIK 68659 CGAGAGAGCAACAUUAGGA 
1110032E23RIK 68659 GCGAAGAUAACUUAAACUU 
1110032E23RIK 68659 GGACUCAUCUCUAGCAUCU 
1110032E23RIK 68659 GGGCUAGAGUAUUACCUAU 
4921511C16 330188 CGCAGGAAGCGGACAUUUA 
4921511C16 330188 GGACACAAGAGGCCAAUAA 
4921511C16 330188 UAACGACCGCUCUGAAUUU 
4921511C16 330188 UUAAGAAGAUCAACUGCGA 
4930412F15RIK 242408 CAGCCAAUAUCCCAGAGUA 
4930412F15RIK 242408 CCAGACAGGUAUCUACAUU 
4930412F15RIK 242408 GGACAUUUGUUGAGAGAAC 
4930412F15RIK 242408 GUAAACACACUCACGAAGA 
4931428F04Rik 74356 AAGCGAGGACAGACGGAUA 
4931428F04Rik 74356 GGUUAUAGACAGACGCUCU 
4931428F04Rik 74356 CGCAGUACGUGCAGGACGA 
4931428F04Rik 74356 AUAGUGUGCUGUUUCGAAA 
6720401E04RIK 101706 CAGCUACGCUCCUUUCUUG 
6720401E04RIK 101706 GAACGGAGCCGCUUUGAAG 
6720401E04RIK 101706 GGACGGCCAUUCUCUAGUA 
6720401E04RIK 101706 GGACUUAAGUAUUGACAGC 
A430057M04RIK 319486 CGUACGACAGGAAGGAAGA 
A430057M04RIK 319486 CUUCAAUGCUACUGCGCUA 
A430057M04RIK 319486 GAACUGCGUCGGGUGAAAU 
A430057M04RIK 319486 GGUCACGUGUGCUGGAGUA 
ACTA1 11459 CAGCCUUCCUUUAUCGGUA 
ACTA1 11459 CAGCUGAACGUGAGAUUGU 
ACTA1 11459 CGGGAGAAGAUGACUCAAA 
ACTA1 11459 GCAAUGAGCGUUUCCGUUG 
Ankib1 70797 GGAGUAUGCUGCCUUAGAC 
Ankib1 70797 GACAAACGAUACCUACAGU 
Ankib1 70797 GUCUGUGGCUGUUAACUAA 
Ankib1 70797 GCCAUAGGCUCAUCUUUAC 
ANKRD1 107765 CCACCGAGCAUGCUUAGAA 
ANKRD1 107765 CGUCUGCGAUGAGUAUAAA 
ANKRD1 107765 GAACCGCUAUAAGAUGAUU 
ANKRD1 107765 UCGCAUAGCUACAUUCUGA 
ARNT2 11864 CAACGGGACAGAACAUAUC 
ARNT2 11864 GGAAUGGACUUCGAUGACG 
ARNT2 11864 GGAGAUGGCGUCAGACAUA 
ARNT2 11864 GUGAAGGUCCCAGUAAAUU 
ART3 109979 CGAAGACGGUACAUCUAUA 
ART3 109979 CGACAGCGUUGUUUUAAUA 
ART3 109979 GAACGCGUUUGACGACGAA 
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Gene Symbol Gene Id Sequence 
ART3 109979 GAGACGACCUUGCGAGAAA 
AVPR2 12000 CAUCUUUGCUCAACGUGAU 
AVPR2 12000 GCAGAUGGUGGGCAUGUAU 
AVPR2 12000 GGAGUUGCGUAGCCUGCUU 
AVPR2 12000 UGACCGAGACCCGCUGUUA 
AW111922 60440 CAAGAUAUAUUCAGGAGUU 
AW111922 60440 CUCAAGAGAUCCUCAAUUU 
AW111922 60440 GGAUUUGGCUGGAAGGAUU 
AW111922 60440 UAUCACAGAUUCAGUCAUU 
B430315C20RIK 327655 GAAGGGUGCUCCAUGGUAC 
B430315C20RIK 327655 GAGCGUGACUUUCGACAAA 
B430315C20RIK 327655 GGUCACUUCUCAGGUAUUA 
B430315C20RIK 327655 UAAAUGAACCUGUGGAGAA 
BC019731 231832 GACCUUGUGCUUCCAAUAU 
BC019731 231832 GAGAAACGCAUGCUGAUUC 
BC019731 231832 GAGGAAUGCGUCAGGGUUU 
BC019731 231832 UAAGAAGAGUCGCAACAUA 
CDC42 12540 CGGAAUAUGUACCAACUGU 
CDC42 12540 GACUACGACCGCUAAGUUA 
CDC42 12540 GCAGUCACAGUUAUGAUUG 
CDC42 12540 UCUAGUAUGUUUCUCAGUG 
Cerkl 228094 GAAUGUAGAUGGUGACUUA 
Cerkl 228094 GCUUGAAGGAGCAACGGAA 
Cerkl 228094 CCCAAAGAGUAAUAGCAAU 
Cerkl 228094 AAGCAUGGCUCUUAGGGUU 
DES 13346 CAACUUGGCUGCCUUCCGA 
DES 13346 GGAGAUCGCGUUCCUUAAG 
DES 13346 GUGACAACCUGAUAGACGA 
DES 13346 UGACUCAGGCAGCCAAUAA 
ENAH 13800 GACAGAAGGCCUUGACUAU 
ENAH 13800 GAGAACGACUAGAACGAGA 
ENAH 13800 GCACUAAUUUGCGAUGUAU 
ENAH 13800 GCAGAAAGAUUCAAGACCA 
FHL1 14199 CGGAGAAGUUCGACUGUCA 
FHL1 14199 GAGACCAGAACGUGGAGUA 
FHL1 14199 GCAAGAUCCUGUGCAACAA 
FHL1 14199 GGAGGUGCAUUAUAAGAAU 
Gm4841 225594 CUUUAUACUAGCCGAUCUA 
Gm4841 225594 UGUUGAAAUGUAAGGAGGA 
Gm4841 225594 GCCAGUAGUAGUAGAAUAA 
Gm4841 225594 GCGAGAAGGAUGUAGUAGU 
HABP2 226243 AGACGGAGAUCCAGGUUUA 
HABP2 226243 GCAAAUACCCUUACACGGG 
HABP2 226243 GCAGGAGACUUAUAACAUG 
HABP2 226243 GUAAGACAGUCAACCAGAA 
HECTD2 226098 GACGACUUGUGCCAGGUUA 
HECTD2 226098 GAUCAGAGUACACCAGUAG 
HECTD2 226098 GUAUUGAAGGGAAUCAUUA 
HECTD2 226098 UCAUGGGACUAGCUGUUUA 
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Gene Symbol Gene Id Sequence 
HRB2 52705 CGAAAUACCGCGAGGCUUA 
HRB2 52705 CGGAGGAAGUUAAGCUCAA 
HRB2 52705 CUACCGAAACUAAGAUUGA 
HRB2 52705 UGAACAGGCAGUACGGAUA 
IGFBP5 16011 AAGAAGGACCGCAGAAAGA 
IGFBP5 16011 CGCAAAGGAUUCUACAAGA 
IGFBP5 16011 GAUGAGACAGGAAUCCGAA 
IGFBP5 16011 UUUCCGAGCUGAAGGCUGA 
LMO6 54630 CAGGACACCUCAACCGAAA 
LMO6 54630 CCACACCGCUCACAACUUC 
LMO6 54630 CGGAGCAGGUUUACCAGUU 
LMO6 54630 GCACAUGGGUCACUUCUGC 
Mars 216443 CGGGAUGCCUUGCGCAGUA 
Mars 216443 GGCCUAACCCCACGGGAAA 
Mars 216443 AGUGCAAUCUGCCGAUAUU 
Mars 216443 GAGCCCUGGAAACGGAUUA 
Med12l 329650 CAGCAUAUUGGCCGAGAAA 
Med12l 329650 CCAAGAUCGGUGCGUAUUU 
Med12l 329650 AGGAAUGUUUGACACGGUA 
Med12l 329650 UCGCAAAGGCAACGAUAGA 
Nppa 230899 ACACAGAUCUGAUGGAUUU 
Nppa 230899 CGAUAGAUCUGCCCUCUUG 
Nppa 230899 CCUCGGAGCCUACGAAGAU 
Nppa 230899 GGGUAGGAUUGACAGGAUU 
PAM 18484 CAAUGCAUGUGUUUGCCUA 
PAM 18484 GAUGGAAAUUAUUGGGUCA 
PAM 18484 GCAAGUUCGUUUACCAACA 
PAM 18484 GCGGGCAUGUACCUUAUGA 
POLR2B 231329 GCGCAGAAGUUUAUUGAUC 
POLR2B 231329 GGACGAUGACGGUUUGAUA 
POLR2B 231329 GGGCAGAUCUCGUGAUGGU 
POLR2B 231329 GUUAAGAAAUCUCACGUAU 
Prss57 73106 CAGCAGACAUUUAGCAUUG 
Prss57 73106 AACGAUAUCUGCCUGCUAA 
Prss57 73106 UCAUGUGGCUCCCUGGUUG 
Prss57 73106 CUGUGAGGCUAUUACGAUU 
RAB20 19332 CCGCUAUCAUCCUUACAUA 
RAB20 19332 GCAGUGGCGUUCCUUCAAC 
RAB20 19332 GGUGGUACCUAUGAUCAUG 
RAB20 19332 UGCCAAGACUGGAUACAAU 
SCYL1 78891 CCAAAUCCCUGGUGACCCA 
SCYL1 78891 CUUCGUGUAUGAUGUGAAA 
SCYL1 78891 GAAGAUUUCUGUCGACACA 
SCYL1 78891 GAGCUGAGCAAGAGUCUAG 
SMARCD3 66993 CAGAGGGACUUCAUGCUAA 
SMARCD3 66993 CAUCAAUGGCGACAAGUAU 
SMARCD3 66993 GAUCAAACCAUCAUGCGGA 
SMARCD3 66993 GCCGCUACUUCUACUGUAA 
SMPD2 20598 CAGCAUGUCUACAGUCUGA 
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Gene Symbol Gene Id Sequence 
SMPD2 20598 CCCAAGAACUGCUACGUCA 
SMPD2 20598 CUACGUGACUCAUCUACAU 
SMPD2 20598 GAUGCACACUACUUCAGAA 
Sorbs2 234214 CUACAGACCUCUUUCGAAA 
Sorbs2 234214 GAAAGACAUUUGCGACCAA 
Sorbs2 234214 CAGAAGUGCAUCACGGGAA 
Sorbs2 234214 GCUUCUUACACUCGAUUUA 
SYNPO2L 68760 AGACAGAUAGUGAUGUUGA 
SYNPO2L 68760 CAGCUAUGCUUAAUGGGCA 
SYNPO2L 68760 GAAAUACUCACCCAACAUC 
SYNPO2L 68760 GGUACCACCUCAGUGAUUU 
TAP1 21354 CCGCAUCACUGACUGGAUU 
TAP1 21354 GACAAGAGCCGCUGCUAUU 
TAP1 21354 GUGCAGGAGUCUCUAGCAA 
TAP1 21354 UGAAAGGCCUUGUGGAGUU 
TESK1 21754 GACCUCCCCUCAACAAUAA 
TESK1 21754 GGAGAGCUGUAUGAUGAGA 
TESK1 21754 GGGAAAUGACUGUCCGCUA 
TESK1 21754 GUUCCACCAUCACCACUUA 
Xirp2 241431 GUAAAGAACUACACUCAUA 
Xirp2 241431 GAGAGGAGCUUAUGCAAAU 
Xirp2 241431 GCAUAUCCAUCCAGAGUUA 
Xirp2 241431 GGAAAGGCGUGCAAAGAAA 
Zmynd15 574428 GCAAGGAAUUCGAUCUCGU 
Zmynd15 574428 GAAGACUGAUUGUCGGAAC 
Zmynd15 574428 CUGGAUACCGAGACGAGUU 
Zmynd15 574428 GCCCAAGGCUCUCAGCGUU 
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Table 4.  RNAseq data 
ID hgnc_symbol Entrez ID log2FoldChange hsa-miR-665 vs Ctrl pvalue 
ENSMUSG00000014837.11 4931428F04Rik 74356 -0.864829 1.06E-04 
ENSMUSG00000090564.5 A430057M04Rik NA -1.2309023 9.35E-08 
ENSMUSG00000031972.4 Acta1 11459 -2.2855283 7.23E-12 
ENSMUSG00000040351.8 Ankib1 70797 -0.2675715 5.74E-01 
ENSMUSG00000024803.8 Ankrd1 107765 -2.8310012 7.57E-29 
ENSMUSG00000015709.8 Arnt2 11864 -1.6305396 1.47E-05 
ENSMUSG00000034842.13 Art3 109979 -1.9655713 1.18E-05 
ENSMUSG00000031390.8 Avpr2 12000 -1.3408918 9.13E-05 
ENSMUSG00000043036.10 Ccdc63 330188 -0.8242056 2.50E-04 
ENSMUSG00000006699.14 Cdc42 12540 -1.3171401 8.90E-04 
ENSMUSG00000075256.6 Cerkl 228094 -1.5412429 5.37E-05 
ENSMUSG00000026208.9 Des 13346 -0.9472144 1.89E-04 
ENSMUSG00000022995.13 Enah 13800 -1.3645253 1.71E-04 
ENSMUSG00000027955.13 Fam198b 68659 -1.5108667 6.96E-05 
ENSMUSG00000043633.6 Fam221b 242408 -0.5971324 5.78E-05 
ENSMUSG00000023092.13 Fhl1 14199 -2.0311443 1.19E-12 
ENSMUSG00000068606.5 Gm4841 225594 -2.2443904 2.51E-06 
ENSMUSG00000025075.11 Habp2 226243 -0.7896597 2.12E-04 
ENSMUSG00000041180.10 Hectd2 226098 -1.1561911 1.60E-05 
ENSMUSG00000026185.8 Igfbp5 16011 -1.3097495 4.48E-06 
ENSMUSG00000063334.13 Krr1 52705 -1.7243245 7.69E-05 
ENSMUSG00000040354.11 Mars 216443 -1.0467266 2.56E-04 
ENSMUSG00000056476.10 Med12l 329650 -0.8566621 2.89E-04 
ENSMUSG00000041616.9 Nppa 230899 -3.7894475 6.42E-34 
ENSMUSG00000066306.9 Numa1 101706 -0.9891489 1.45E-03 
ENSMUSG00000026335.13 Pam 18484 -0.9936884 1.22E-04 
ENSMUSG00000029250.5 Polr2b 231329 -0.7333303 7.18E-04 
ENSMUSG00000033526.13 Ppip5k1 327655 -1.2198184 3.55E-04 
ENSMUSG00000031145.12 Prickle3 54630 -0.7954645 8.64E-05 
ENSMUSG00000020323.11 Prss57 73106 -1.0416156 1.54E-06 
ENSMUSG00000031504.5 Rab20 19332 -0.9538548 3.58E-04 
ENSMUSG00000018040.6 Rrp7a 74778 -0.5738517 2.33E-04 
ENSMUSG00000024941.8 Scyl1 78891 -0.9593912 3.14E-05 
ENSMUSG00000028949.10 Smarcd3 66993 -0.6519333 1.30E-04 
ENSMUSG00000019822.9 Smpd2 20598 -0.7261175 1.77E-04 
ENSMUSG00000031626.13 Sorbs2 234214 -0.9637293 1.48E-03 
ENSMUSG00000039376.10 Synpo2l 68760 -1.3764994 1.51E-03 
ENSMUSG00000037321.14 Tap1 21354 -1.6035044 4.34E-04 
ENSMUSG00000028458.9 Tesk1 21754 -2.1044271 6.29E-06 
ENSMUSG00000036687.10 Tmem184a 231832 -0.8635794 3.81E-05 
ENSMUSG00000027022.10 Xirp2 241431 -2.5783339 9.97E-24 
ENSMUSG00000040829.11 Zmynd15 574428 -1.388588 1.97E-04 
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